

## Targeting immune dysfunction in aging

Borgoni, Simone; Kudryashova, Ksenia S.; Burka, Ksenia; De Magalhães, João Pedro

DOI:

[10.1016/j.arr.2021.101410](https://doi.org/10.1016/j.arr.2021.101410)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

Borgoni, S, Kudryashova, KS, Burka, K & De Magalhães, JP 2021, 'Targeting immune dysfunction in aging', *Ageing Research Reviews*, vol. 70, 101410. <https://doi.org/10.1016/j.arr.2021.101410>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.



## Review

## Targeting immune dysfunction in aging

Simone Borgoni<sup>a,b,\*</sup>, Ksenia S. Kudryashova<sup>a</sup>, Ksenia Burka<sup>a</sup>, João Pedro de Magalhães<sup>a,c</sup><sup>a</sup> Centaura AG, Bleicherweg 10, Zurich, 8002, Switzerland<sup>b</sup> Institute of Experimental Immunology, University of Zurich, Zurich, 8057, Switzerland<sup>c</sup> Integrative Genomics of Ageing Group, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, L7 8TX, UK

## ARTICLE INFO

## Keywords:

Healthy longevity  
 Geroscience  
 Inflammation  
 Immune system  
 Anti-aging  
 Immunosenescence

## ABSTRACT

Human aging is a multifactorial phenomenon that affects numerous organ systems and cellular processes, with the immune system being one of the most dysregulated. Immunosenescence, the gradual deterioration of the immune system, and inflammaging, a chronic inflammatory state that persists in the elderly, are among the plethora of immune changes that occur during aging. Almost all populations of immune cells change with age in terms of numbers and/or activity. These alterations are in general highly detrimental, resulting in an increased susceptibility to infections, reduced healing abilities, and altered homeostasis that promote the emergence of age-associated diseases such as cancer, diabetes, and other diseases associated with inflammation. Thanks to recent developments, several strategies have been proposed to target central immunological processes or specific immune subpopulations affected by aging. These therapeutic approaches could soon be applied in the clinic to slow down or even reverse specific age-induced immune changes in order to rejuvenate the immune system and prevent or reduce the impact of various diseases. Due to its systemic nature and interconnection with all the other systems in the body, the immune system is an attractive target for aging intervention because relatively targeted modifications to a small set of cells have the potential to improve the health of multiple organ systems. Therefore, anti-aging immune targeting therapies could represent a potent approach for improving healthspan. Here, we review aging changes in the major components of the immune system, we summarize the current immune-targeting therapeutic approaches in the context of aging and discuss the future directions in the field of immune rejuvenation.

## 1. Introduction

Scientific and medical developments during the last century allow humans to live healthier and longer. The latest data from the United Nations reveals that one in eleven people in the world is over age 65 (9%) and by 2050 this will rise to one in six (16%). Additionally, the number of humans over 80 is projected to triple, from 143 million in 2019 to 426 million in 2050 (United Nations, 2019). Unfortunately, the aging of the global population is accompanied by an increase in the incidence of age-related diseases which in turn impair the quality of life of the elderly. One of the biggest challenges of this century is promoting healthy aging, which is achievable both by changes in lifestyle and therapeutic interventions.

Aging is a multifactorial phenomenon that affects virtually all cells and organ systems in the human body resulting in a progressive functional impairment and loss of homeostasis. One of the most dysregulated systems in aging is the immune system, with alterations in several

biological and physiological processes that have significant repercussions on the overall well-being of the organism (López-Otín et al., 2013) (Fig. 1). The main roles of the immune system include the defense of the host against pathogens, the maintenance of homeostasis with clearance of dead cells and the regulation of healing processes. These activities are performed by specialized cells, that can activate general immune responses (innate immunity) or build specialized long-lasting defense against specific antigens (adaptive immunity). The progressive deterioration of the immune system affects both of these systems in elderly individuals, increasing susceptibility to infections, cancer and inflammatory diseases, while delaying wound healing processes and reducing the ability to build an antibody response to some types of vaccination (Barbé-Tuana et al., 2020; Pereira and Akbar, 2016; Weyand and Goronzy, 2016). Indeed, the incidence of several infectious diseases, both bacterial and viral, increases with age and can be modeled based on immune system decline (Palmer et al., 2018). In the same computational study, Palmer et al. showed that this is also true for cancer, indicating

\* Corresponding author at: Centaura AG, Bleicherweg 10, Zurich, 8002, Switzerland.  
 E-mail address: [info@centaura.com](mailto:info@centaura.com) (S. Borgoni).

<https://doi.org/10.1016/j.arr.2021.101410>


Received 7 April 2021; Received in revised form 28 June 2021; Accepted 14 July 2021

Available online 17 July 2021

1568-1637/© 2021 The Authors.

Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



**Fig. 1.** Immune cells and general changes in aging. Schematic representation of the immune system, with the differentiation of distinct immune cells, their physiological role in innate and adaptive immunity and the consequences of alterations during aging.

that the alteration of the immune system in aging may contribute to increased cancer incidence in the elderly (Palmer et al., 2018). This work expands the scientific evidence on the relation between aging, immunity and cancer, but the exact ways in which they affect and influence each other remains debatable (De Magalhães, 2013; Fane and Weeraratna, 2020). Also autoimmune diseases have been investigated in the context of aging, with some evidence suggesting that they tend to be less frequent and less severe in elderly individuals (Watah et al., 2017), consistent with an overall decline in immune cell activity.

Another notable example of the importance of robust immune response in healthy aging is the recent COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that has a drastic effect on the elderly, especially those with co-morbidities. Indeed, age has been defined as a strong risk factor for disease severity and mortality upon infection with SARS-CoV-2, and this is strongly connected to the immune dysfunction that characterizes the elderly (Cunha et al., 2020; Domingues et al., 2020; Verity et al., 2020). Notably, an inefficient antigen-specific response, caused by alterations of cells of the adaptive immunity (particularly naïve T cells) in patients older than 65, contributes to poor disease outcome (Rydzynski Moderbacher et al., 2020). Additionally, individual differences in immune features of COVID-19 patients add a further layer of complexity (Mathew et al., 2020): immune dysfunction in the elderly cannot be generalized and individual differences can affect the outcome, vaccine efficacy and treatment response.

The dysfunctional immune system in aging has been associated with two processes defined as “immunosenescence” and “inflammaging”. Immunosenescence, first proposed more than 40 years ago, is defined by


the gradual deterioration of the immune system, which loses its ability to respond to infections and build effective long-lasting immune memory (Aiello et al., 2019; Aw et al., 2007; Walford, 1969). More recently, studies have highlighted how several cell types of the innate and adaptive immune system undergo phenotypic changes during aging that impair their basic functions. At the beginning of 2000, a second phenomenon that affects the immune system in aging was proposed, termed inflammaging (Franceschi et al., 2000). While inflammatory processes are essential for the defense against foreign pathogens and clearance of dead and aberrant cells, their dysregulation and overactivation in the elderly causes a chronic inflammatory state that persists and promotes the development of inflammatory diseases associated with aging. These two processes are deeply interconnected, and can influence and maintain each other to create an imbalanced immune environment that is not only dysfunctional, but even acts as a driver for diseases development (Fulop et al., 2018). Individual differences are now starting to delineate a personalized way of aging that adds complexity to the investigation of deregulated processes (Ahadi et al., 2020; Mathew et al., 2020; Sayed et al., 2019). In this view, the identification of different immune ageotypes will help define subpopulations of elderly individuals with characteristic immune signatures and their longitudinal monitoring might help develop potential personalized anti-aging treatments (Alpert et al., 2019). In this review, we report and discuss the contributions of different immune cells in aging and address the latest therapeutic options that have been proposed with the overall goal to rejuvenate or at least revitalize the immune system and slow down or even reverse immune aging.

## 2. Therapeutic targeting of immune precursors

Hematopoietic Stem Cells (HSCs) are responsible for the production of all blood cells in vertebrates, being able to differentiate into both myeloid and lymphoid precursors. Balancing their self-renewal and differentiation potential, they maintain immune homeostasis in the body throughout the whole lifetime of an organism. Even though extremely resilient, the HSC compartment is highly affected by aging, losing some of its fundamental properties during the aging process (Lee et al., 2019) (Fig. 2). Being the source of all immune cells, changes in HSCs can drastically affect several immune processes and populations. In old mice, phenotypic and functional changes in the adaptive immune system are primarily driven by HSCs aging (Leins et al., 2018). In a recent article, the deletion of *Erc1*, an important DNA repair protein, in murine HSCs induced a selective increase of DNA damage in immune cells and early immunosenescence. This resulted not only in impaired immune function but also in systemic premature aging, which could be attenuated by young immune cells transplantation (Yousefzadeh et al., 2021).

While healthy HSCs are able to maintain appropriate proportions of the downstream lineage-specific progenitors, in the elderly HSCs differentiation is skewed towards the myeloid lineage, resulting in a reduced output of lymphoid progenitors (Pang et al., 2011). Additionally, aging reduces HSCs self-renewing potential, progressively decreasing their capacity to repopulate the blood after stress (De Haan and Lazare, 2018). Indeed, in younger mice HSCs perform much better compared to older mice HSCs after transplantation, indicating higher potency (Dykstra et al., 2011; Rossi et al., 2005; Verovskaya et al., 2013). The reason for this reduced potential has been intensely investigated, and several factors have been found to play a role. One is DNA damage, with evidences of an increase in double strand DNA breaks in

aged human HSCs (Rübe et al., 2011). Similarly, aging HSCs produce higher levels of reactive oxygen species (ROS), which induces oxidative stress in HSCs, promoting senescence and apoptosis (Lee et al., 2019). Particularly relevant in this context is p38, a mitogen-activated protein kinase which has been found to have high activity in aged tissues and is known as a key regulator of stress pathways and as a strong ROS inducer (Hsieh and Papaconstantinou, 2002; Li et al., 2011). Indeed, p38 inhibitors are able to rejuvenate murine HSCs and increase their potency (Ito et al., 2006; Jung et al., 2016). Other important proteins involved in oxidative stress control are sirtuins. Specifically, Sirt3 is downregulated in the HSCs of aged mice and correlates with increased ROS-stress. Its overexpression reverts the phenotype, decreases ROS levels and increases the potency of these cells (Brown et al., 2013). Recently it was also reported a central role of chaperone-mediated autophagy (CMA), a selective type of autophagy that involves motif-specific lysosomal degradation of proteins, in the sustainment of HSCs functions (Dong et al., 2021). In HSCs from old mice CMA activity is drastically decreased, and its pharmacological reactivation restores HSCs function both in mice and humans (Dong et al., 2021). An additional factor for the reduced potency and replication abilities of HSCs during aging may be the progressive shortening of telomeres. Indeed, it was demonstrated in mice that HSC proliferation is accompanied by a decrease in telomere length and that telomerase is essential in maintaining HSC proliferative capabilities (Allsopp et al., 2003, 2001). HSCs from mice with short telomeres show high DNA damage levels and become senescent (Wang et al., 2014). Pot1, a telomere-binding protein, has been reported to be essential in maintaining HSCs activity in aging and its overexpression promoted self-renewal and reduced the DNA damage response and ROS production *in vitro* (Hosokawa et al., 2017). Moreover, telomere dysfunction causes drastic changes in mouse bone marrow promoting aging, including myeloid skewing and increased cytokines production



**Fig. 2.** Immune alterations during aging. Depiction of the main alterations that affect immune cells during aging, which ultimately result in higher susceptibility to infections, increased incidence of age-related diseases as cancer and diabetes, chronic inflammation, and reduced vaccination efficacy.

(Ju et al., 2007). Targeting this dysfunction by gene therapy-mediated telomerase activation was sufficient to replenish the blood cell counts and improve survival in a mouse model of anemia (Bär et al., 2016). Similar approaches could potentially be applied to aging, bearing in mind that telomerase expression might promote cancer initiation and should therefore be carefully implemented to avoid detrimental effects.

Recent studies in mice demonstrated a central role of cell division control protein 42 (cdc42) in HSC aging (Florian et al., 2018; Leins et al., 2018). Elevated cdc42 activity in these cells causes loss of polarity and a reduction in the number of lymphoid precursors (Florian et al., 2013). Consistently, cdc42 inhibition successfully reverts the phenotype and promotes rejuvenation of the HSC compartment, as well as reconstitutes the immune system activity (Leins et al., 2018). Among several inhibitors available to target this protein, the small-molecule CASIN shows great potential for its ability to specifically target cdc42 and mobilize murine HSCs (Liu et al., 2019). In addition, CASIN administration in aged mice restores the physiological level of cytokines and is able to increase overall lifespan (Florian et al., 2020). Targeting cdc42 is beneficial in reversing aging not only in HSCs, but also in other stem cells compartments, such as mesenchymal stem cells derived from rat and human adipose tissues (Chaker et al., 2018; Umbayev et al., 2018). This suggests that cdc42 is a promising target for general rejuvenating therapies that influence multiple systems, though further studies are needed regarding its applicability to humans and potential side effects.


Another approach proposed for the rejuvenation of the HSCs compartment is bone marrow (BM) transplant. Indeed, BM transplant from young donors to old mice is able to increase lifespan by 30 % (Kovina et al., 2019). Also, BM transplant is able to improve learning and memory in old mice, suggesting this approach may be beneficial in the treatment of age-associated neurodegenerative diseases (Das et al., 2019). In humans, DNA methylation age of reconstituted blood following allergenic HSCs transplantation reflects the age of the donor and not the one of the recipient, even 17 years after transplantation

(Søraas et al., 2019). This shows a potential for HSCs transplantation from younger donors to older individuals that may have a rejuvenating effect on the immune system. As cellular precursors of all immune cells, HSC rejuvenating therapies are showing great promise: restoring a more normal phenotype and rebalancing the immune system at source with effects on several downstream immune processes (Fig. 3).

### 3. Therapeutic targeting of the lymphoid lineage

#### 3.1. T cells

T lymphocytes, together with B cells (described in detail below), are the main players in adaptive immunity. Through their unique T cell receptor (TCR), T cells are responsible for the recognition of foreign antigens displayed by antigen presenting cells (APCs), and the activation of specific host defense measures. The two main T cells populations, CD4+, mostly involved in orchestrating the response of other immune cells, and CD8+, generally exerting their cytotoxic effect on infected or damaged cells, are affected differently during aging (Fig. 2). In terms of blood count numbers, while CD4 + T cells are not affected, the CD8+ cytotoxic subset shows a strong decrease in the elderly, and can be considered one of the markers of immune aging (Goronzy and Weyand, 2019; Whiting et al., 2015). Additionally, activated CD8+ cells display features of cellular senescence and gain a virtual differentiated memory phenotype, therefore reducing the functional naïve T cells compartment, and influencing their ability to respond to new infections (Quinn et al., 2018; Sprent and Surh, 2011). The dynamics inside specific sub-populations is also strongly influenced by aging: in mice, the CD4+ subsets is skewed towards the extremes, with accumulation of pro-inflammatory CD4 + T cells with acquired cytotoxic phenotype (CTLs) and anti-inflammatory T regulatory cells (Tregs) (Elyahu et al., 2019). Tregs changes during aging are still being debated. On one hand, it has been shown that in aged mice Tregs are higher in number and



**Fig. 3.** Immune interventions to reverse immune aging. Representation of the most promising therapeutic interventions targeting immune cells. Rejuvenation of the immune system could be achieved from different directions and combining drugs that target distinct dysfunctional cell types.

more suppressive compared to Tregs from young mice (Garg et al., 2014). On the other hand, it was reported that Tregs senesce more than other T cells, and Tregs from old mice are less able to exert their suppressive function compared to their young counterparts, contributing to increased inflammaging (Guo et al., 2020). Finally, other CD4+ subtypes such as T helper type 1 and type 17 cells have been shown to be dysfunctional in the elderly and may contribute to increased susceptibility to infections (Coakley et al., 2019; Dillon et al., 2020).

Circulating T cells are known to proliferate in response to IL7 produced in lymph nodes and the thymus. However, the levels of this cytokine progressively decreases with age (Fry and Mackall, 2005). The age-induced fibrosis of lymph nodes, combined with a decrease in IL7R on T cells, results in a further reduction of T cell numbers in the elderly (Kityo et al., 2018; Ucar et al., 2017). Clinical trials in HIV patients demonstrate that recombinant human IL7 treatment increases both CD4+ and CD8 + T cells, as well as induces their activation (Rosenberg et al., 2006; Lévy et al., 2012). This approach could also be tested in healthy elderly patients to restore the physiological levels of T lymphocytes (Nguyen et al., 2017).

T cells function through recognition of antigens presented on the MHC (major histocompatibility complex) molecules on target cells through their TCR. Upon aging the number of T cells with different TCRs is highly reduced, decreasing the ability to recognize a broad spectrum of antigens, and this correlates with impaired immune responses (Yager et al., 2008; Yoshida et al., 2017). Notably, in old individuals clonal populations of T cells with the same TCR may rise up to as much as 25 % of the total CD8 + T cell compartment (Aiello et al., 2019). The shrinkage of the CD8+ repertoire has been also associated with chronic infections in humans, with CMV-seropositive individuals showing accumulation of CD8+ clonal populations (Hadrup et al., 2006). This may drastically decrease the recognition power of CD8 + T cells, increasing the susceptibility to new infections and cancer development.

Upon aging, differentiated T cells gain some specific features such as increased DNA damage, short telomeres, and increased production of inflammatory cytokines which can be associated with a senescence-like state (Pangrazzi and Weinberger, 2020). These T cells become highly inflammatory, while at the same time reducing their antigen specificity, harming healthy tissues (Covre et al., 2020). Even though no combination of markers is currently validated to characterize senescent T cell subsets completely and exclusively, some important suggestions have been proposed. Lymphocytes with a reduced expression of CD28, a co-stimulatory molecule required for T cells activation, show a “senescence-like” phenotype, are associated with several age-related diseases and show reduced antigen-dependent proliferation, short telomeres and increased inflammatory cytokine production (Pangrazzi and Weinberger, 2020). Additionally, it has been proposed that a subpopulation of human CD28- cells characterized by the increased expression of CD57 shows even more senescent-like features such as higher production of pro-inflammatory molecules and high ROS level (Pangrazzi et al., 2020). Other groups characterized the loss of the co-stimulatory marker CD27 as an additional senescence-related marker on CD28- T cells. It is now proposed that the loss of both of these markers defines a more differentiated and senescent-like population of T cells (Pangrazzi and Weinberger, 2020; Weng et al., 2009). Attempts to characterize CD4+ senescent cells identified CD45RA + CD27- as a subpopulation with typically senescent features (Henson et al., 2014). These markers were also recently confirmed in CD8+ cells, identifying CD45RA + and CD27 as more general senescent markers for human T lymphocytes (Callender et al., 2018). Notably, during aging senescent-like CD8 + T cells switch from the typical TCR-mediated activity to a NK-like activity by expressing protein complexes typical of NK cells (Pereira et al., 2020). The expression of NK receptors and the concomitant reduction in TCR levels allows these cells to recognize and kill other cells in an antigen-independent way, however reducing their contribution to the adaptive immune response. This phenotypic switching is mediated by sestrins (stress-inducible proteins that regulate

metabolism through sensing nutrient levels and redox status) and their blockade is able to restore T cells functions, as well as enhance influenza vaccine response in old mice (Lanna et al., 2017; Pereira et al., 2020).

The presence of specific protein markers that identify senescent T cells could open the possibility for therapies targeting these specific populations without affecting normal immune system functions. A notable example is the recent development of a CD153 peptide vaccine, that using a specific peptide was able to induce high production of anti-CD153 antibodies (Yoshida et al., 2020). CD153 has been proposed as a marker of senescent-like T cells infiltrating the adipose tissue, responsible for increased inflammation and metabolic disorders (Shirakawa et al., 2016). CD153 vaccination was found to be well tolerated and effective in the reduction of CD153+ senescent T cells in the adipose tissue of diet-induced obese mice, as well as in the restoration of metabolic balance to improve aging and obesity-related metabolic disorders (Yoshida et al., 2020).

As discussed for HSCs, T cells are also affected by telomere shortening. Indeed, T cells from healthy centenarians show longer telomeres and higher telomerase activity in response to stimulation compared to other centenarians (Tedone et al., 2019). Additionally, a specific subset of T cells, characterized by CD28 expression, is able to maintain a strong telomerase activity upon stimulation, in agreement with the identification of the loss of CD28 as one of the T cell senescent markers previously mentioned (Huang et al., 2017; Pangrazzi and Weinberger, 2020). Several therapeutic strategies for telomere elongation or telomerase induction are currently under investigation (Martínez and Blasco, 2017). Among others, sestrin inhibition shows great promises by increasing telomerase activity and elongating telomeres in murine senescent T cells via p38 inhibition (Lanna et al., 2017). The development of new anti-senescence therapies and their application in T-cell re-activation could help strengthening adaptive immunity in the elderly (Fig. 3).

### 3.2. B cells

B cells are essential for adaptive immunity through their antigen presenting and antibody production capacities. It is widely accepted that during aging B cells produce less antibodies and with lower affinity, impairing the ability of the elderly to respond to new infections and vaccinations (Kogut et al., 2012) (Fig. 2). In particular, the decrease in vaccination efficacy with age is caused by a reduction in the IgM repertoire and their levels in the bloodstream upon immunization (Park and Nahm, 2011). Recently, a subset of B cells renamed aged-associated B cells (ABCs) were identified. In mice, the number of ABCs in the bone marrow and spleen increases with age (Ratliff et al., 2013) and these increased levels closely correlate with immune senescence as well as inflammaging (Cancro, 2020). It was reported that specific toll-like receptors (TLRs), responsible for pathogens recognition, such as TLR7 and TLR9, are required for ABC differentiation, together with stimulatory cytokines such as IL-21 and IFN $\gamma$  (Naradikian et al., 2016). This suggests that these markers may be suitable targets for anti-aging therapies that aims to specifically deplete this subpopulation, without interfering with the normal B cell compartment (Rubtsov et al., 2017). Also the B-1 subpopulation of B cells, important in antimicrobial and housekeeping antibody production, decreases during human aging (Rodríguez-Zhurbenko et al., 2019). Apart from B-1 changes in number, their ability to secrete IgM is highly impaired, implicating them in increased susceptibility to infection and reduced quality of life (Holodick and Rothstein, 2015; Rodríguez-Zhurbenko et al., 2019). Another recent age-associated subpopulation of B cells is the aged adipose B cells (AABs), resident in fat associated lymphoid clusters and phenotypically different from ABCs (Camell et al., 2019). AABs express high levels of IL-1R and are induced by IL-1 $\beta$  and IL-18. Both an antibody treatment against the B cell marker CD20 and the IL-1R antagonist (IL-1RA) reduce AABs and increase lipolysis in mice, showing promise as anti-aging therapies (Camell et al., 2019).

The balance between B cell subpopulations might therefore be a prominent factor in aging, but further studies are needed to advance novel ways to specifically target age-promoting populations of B cells such as ABCs and AABs. In addition, overall B cell depletion with a cocktail of B cell specific markers CD19, B220 and CD22 showed promising results by inducing the rejuvenation of the B cell compartment through the reactivation of B cell lymphopoiesis in murine bone marrow (Keren et al., 2011). However, while this approach rejuvenated the circulating B cells compartment, it was not able to restore immune competence and vaccination responses in old mice (Avivi et al., 2019). Therefore, further studies are needed to demonstrate if a combination of B cell depletion with other anti-aging strategies may be effective in the restoration of immune competence in elderly individuals (Fig. 3).

### 3.3. Natural killer cells

Natural Killer (NK) cells are an important lymphoid population involved in innate immune defense. However, due to their ability to retain antigen-specific memory, NK cells are now considered also part of the specialized adaptive immune system (Nikzad et al., 2019; Paust and Von Andrian, 2011). NK cells have been shown to undergo several phenotypic and functional changes during aging (Xavier Camous et al., 2012) (Fig. 2). NK cells are characterized by the expression of the adhesion protein CD56 and the level of expression of this marker can distinguish two subpopulations with different functions: CD56<sup>bright</sup> cells, mostly involved in cytokine production, and CD56<sup>dim</sup> proficient cytotoxic cells (Gounder et al., 2018). The ratio of CD56 NK cells is important for the maintenance of a functioning immune system, and it is impaired in aging with a decrease of CD56<sup>bright</sup> and an increase in the number of CD56<sup>dim</sup> cells (Borrego et al., 1999; Gayoso et al., 2011). In addition, IL-2 induction of NK cells in the elderly fails to evoke sufficient proliferation and activation, with a switch in cytokine production (Almeida-Oliveira et al., 2011; Rink et al., 1998). NK cells are also thought to be pivotal in the removal of senescent cells in the organism, and their alteration during aging results in an accumulation of these deleterious cells (Song et al., 2020). Indeed, strategies targeting NKG2A, a receptor involved in the inhibition of NK cell cytotoxic activation, show promising effects in reducing the number of senescent cells in mice by restoring NK cellular immunity (André et al., 2018; Kamiya et al., 2019; Pereira et al., 2019) (Fig. 3). Additionally, the possibility to engineer chimeric antigen receptor (CAR)-NKs (Wang et al., 2020) specifically towards cellular senescence targets may represent a novel way to safely reduce the effects of aging and the accumulation of senescent cells.

## 4. Therapeutic targeting of the myeloid lineage

### 4.1. Macrophages

Macrophages are essential cells of the innate immunity compartment involved in protection against foreign pathogens, as well as one of the main APCs important in T cells activation. Several studies have shown that during aging macrophage functions are reduced or impaired, impacting the ability of these cells to build up a proper immune response (Fig. 2). Indeed, macrophages in elderly have reduced TLRs (Renshaw et al., 2002), increasing susceptibility to infections, as well as lower expression of MHC II, resulting in a decreased ability to present antigens to T cells (Herrero et al., 2002). Additionally, aged macrophages have altered inflammatory cytokine production, and increased release of suppressive cytokines such as IL-10 and prostaglandins (Stahl and Brown, 2015). This is confirmed by a reduced ability of macrophages to polarize towards the M1 pro-inflammatory phenotype and to properly activate an inflammatory response (Allavena et al., 2008). However, aged murine macrophages maintain enough plasticity to be induced through targeted IL-2/anti-CD40 therapy and are able to regain their T cell activation capacities (Jackaman et al., 2013). Conversely, aged macrophages also show high-inflammatory features characteristic of the

M1 phenotype, in line with the general inflammatory state persistence in the elderly (Clark et al., 2020). Changes in macrophage phenotypes upon aging are also related to metabolic alterations. Among other cell types, macrophages are highly affected by decreased autophagy, altered nutrient sensing abilities and mitochondrial dysfunction associated with aging (van Beek et al., 2019). Caloric restriction or metabolic targeting drugs such as metformin, resveratrol and rapamycin might therefore exert their effect on lifespan through a direct action on the macrophage population (Fabbiano et al., 2016; Vasamsetti et al., 2015). Importantly, inflammation resolution is highly impaired and longer lasting in the elderly (De Maeyer et al., 2020). The cause of this impaired inflammation resolution can be identified in a reduction of TIM-4 receptor on macrophages caused by hyperactive p38 activity. Notably, an orally administered p38 inhibitor in the elderly is able to decrease TIM-4 expression and may help to restore macrophage ability to resolve inflammation (De Maeyer et al., 2020). In addition, inhibition of p38 is able to reduce local inflammation through a decrease of CCL2-mediated inflammatory monocyte recruitment, therefore increasing specific antigen responses (Chambers et al., 2021). This novel approach could represent an efficient therapeutic option to treat inflammatory age-related diseases, but additional studies with larger cohorts are needed to prove efficacy and identify potential side effects (Fig. 3).

### 4.2. Dendritic cells

Dendritic cells (DCs) are proficient APCs involved in both innate and adaptive immunity and tolerance. In their unique role, they are capturing antigens in different tissues and then migrate to the lymph nodes to interact with T and B lymphocyte to build up the adaptive immune response (Hammad and Lambrecht, 2008; Novak et al., 2010). They are subdivided in myeloid DCs (mDCs), a peripheral subset resident in tissues, and plasmacytoid DCs (pDCs), mostly found in the circulation. While they have overlapping functions, they are specialized in the production of particular cytokines and present different TLRs on their surface (Agrawal et al., 2018; Sallusto and Lanzavecchia, 2002). While overall DCs numbers are not altered during aging, specific subsets have been shown to change. Notably CD141<sup>+</sup> DCs, known to be involved in viral response, are decreased in the elderly, which can be one of the reasons of increased susceptibility to viral infection at advanced ages (Agrawal et al., 2016). In addition, post-menopausal women have lower numbers of pDCs, their DCs produce less cytokines compared to young women and are less responsive to stimulation (van Splunter et al., 2019). A recent study identified a subset of DCs, cDC2, that may be responsible for the reduced vaccination efficacy in the elderly. Indeed, when this subset activity was boosted with imiquimod, a TLR7 agonist, the vaccination efficacy in mice was partly restored (Stebeeg et al., 2020). As DCs are just one of the players involved in antibody responses, the combination of this drug with strategies targeting other immune populations might help in restoring a functional antigen-response for long-term vaccination efficacy in elderly (Fig. 3).

### 4.3. Granulocytes

Granulocytes (neutrophils, basophils, eosinophils and mast cells) are innate immunity cells that are able to activate efficient inflammatory programs upon pathogen infection or loss of tissue homeostasis. While their role in aging has been less studied compared to other immune cells, several changes have been identified in the elderly and their importance in maintaining aged tissue homeostasis (Fig. 2). Aging impacts the neutrophil compartment inducing changes in their basic activities, such as peroxide production, chemotaxis and apoptosis (Fulop et al., 2004; Tortorella et al., 1998). Additionally, aged mice display higher levels of senescent neutrophils, characterized by high expression of the chemokine receptor CXCR4 and low expression of the naïve marker CD62 L (Frisch et al., 2019). Also, the number of basophils increases with age and the expression of specific surface markers are altered, impairing

their activity (Van Beek et al., 2018). Finally, recent data also highlighted the important role of eosinophils in aging (Brigger et al., 2020). This novel study showed that eosinophils from aged adipose tissue display impaired tissue homeostasis ability, promoting systemic inflammation. Notably however, eosinophils transfer from young mice rescued these phenotypes and resulted in a striking systemic rejuvenation of the recipient mice mediated by restored IL-4 production (Brigger et al., 2020).

#### 4.4. Microglia

Microglia are specialized cells in the central nervous system responsible for maintenance of homeostasis and immune responses. Opposite to macrophages, microglia cells are known to have increased inflammatory properties during aging, with high production of pro-inflammatory cytokines in response to external stimuli, but reduced phagocytosis and chemotaxis capabilities (Rawji et al., 2016). These alterations have been extensively associated with age-related neurodegenerative diseases such as Alzheimer's disease (Norden and Godbout, 2013). Indeed, monophosphoryl lipid A, an inducer of chemotaxis and phagocytosis, increases microglia's phagocytosis capability and improves Alzheimer's clinical outcome in mice (Michaud et al., 2013). In addition, the promotion of a regulatory phenotype with the selective nuclear receptor PPAR $\alpha/\gamma$  modulator DSP-8658 induced better clinical outcomes, through decreased secretion of pro-inflammatory cytokines and increased phagocytic abilities in a murine model of Alzheimer (Yamanaka et al., 2012). CD22 expression, a negative regulator of phagocytosis, is elevated in microglia. CD22 antibody blockade successfully reversed the transcriptional signature of aging brains in mice and improved cognitive functions (Pluvinaige et al., 2019). Given the high expression of CD22 in Alzheimer's human brain (Friedman et al., 2018), CD22 could be a promising candidate for targeted therapies aiming to rejuvenate the human brain through the restoration of microglial phagocytic functions. Recent data also shows a role of prostaglandin E2 signaling in microglia and macrophages in mouse brain aging and cognitive decline (Minhas et al., 2021). In aged mice, inhibition of prostaglandin E2 receptor EP2 in the myeloid compartment restored cognitive functions, through a rejuvenation of cellular metabolism as well as systemic and neural inflammation (Minhas et al., 2021).

### 5. Other immune-targeting strategies

#### 5.1. Thymus regeneration

The thymus is an immune organ involved in T cell maturation. It atrophies at puberty and progressively loses functionality during adulthood, reducing its ability to eliminate self-reacting T cells responsible for increased inflammation (Thomas et al., 2020). Thymus function is strongly regulated by FOXN1, a transcription factor expressed by thymic epithelial cells responsible for thymocyte development and differentiation (Vaidya et al., 2016) (Fig.2). FOXN1 expression in the thymus decreases with age and is the main cause of thymus involution, which occurs relatively early during the life course (Rode et al., 2015; Sun et al., 2010). The importance of this single factor in thymic function makes it an extremely attractive target for thymic rejuvenation therapies. Gene therapy inducing FOXN1 overexpression in the murine thymus reverses the aged thymus phenotype and restores its function (Sun et al., 2010). Similarly, the transplant of thymus epithelial stem cells with high expression of FOXN1 reverses age-related murine thymic involution (Kim et al., 2015). Of note, ectopic thymus created from reprogrammed fibroblasts also increases the number of naïve T cells in mice and expands the possibilities for thymus rejuvenation (Bredenkamp et al., 2014). Additionally, FOXN1 reprogrammed embryonic fibroblasts engrafted in the thymus of aged mice rejuvenates the overall thymic architecture, reduces both the number of senescent T

cells and inflammaging (Oh et al., 2020). These findings open new clinical possibilities to reverse thymic involution in humans using autologous reprogrammed fibroblasts to restore central tolerance and reduce inflammation in the elderly. In another thymus reconstitution study, decellularized rat thymi stuffed with *ex vivo* expanded thymic epithelial and interstitial cells of human origin were successfully transplanted into humanized immunodeficient mice (Campinoti et al., 2020). In mice followed for over five months after transplantation, the transplanted thymi show capacity to support T cells development and maturation into physiological human CD4 $^{+}$ /CD8 $^{+}$  ratio. Also, supplementation of exogenous factors such as KGF, IGF-1 and BMP4 improves thymic functionalities in mice, thus representing putative regenerative strategies that should be investigated for their potential in humans (Chu et al., 2008; Min et al., 2007; Wertheimer et al., 2018). Of particular interest are cytokine therapies using IL-7 and IL-22, which are under investigation considering their involvement in thymus homeostasis regulation. IL-7 is a cytokine produced by stromal cells that stimulates survival and differentiation of thymocytes and T cells. It has been reported that IL-7 supplementation reverses age-associated thymus atrophy and reactivate its functionality in old mice (Andrew and Aspinall, 2001; Henson et al., 2005). However, while clinical trials studying the effect of IL-7 administration in humans showed an increase in lymphocytes numbers in several disease settings, no specific effect on thymus was observed (Rosenberg et al., 2006; Sportès et al., 2010; Trédan et al., 2015). Specific studies are therefore required to investigate IL-7 immune-rejuvenating effects on healthy elderly.

However, the beneficial effects of thymus rejuvenation can be counteracted by secondary lymphoid organ degeneration (Thompson et al., 2019). Efficient strategies should therefore aim to combine thymus with lymph nodes regeneration: anti-fibrotic or senolytic drugs might help in this direction by reducing lymph node fibrosis and remodeling their degenerated structure. Alternatively, synthetic lymph nodes may efficiently acquire the properties of the lymphatic tissues *in vivo* and restore immune functions (Lenti et al., 2019). This approach could open novel possibilities for the rejuvenation of the lymphatic system and could be combined with other strategies to allow a long-lasting restoration of the immune function (Fig. 3).

#### 5.2. Targeting immune metabolism

During aging, cells of the body undergo metabolic reprogramming that allows them to modify their nutrient sensing capabilities and to modulate their need for energy (Barzilai et al., 2012; López-Otín et al., 2013). Several metabolic-targeting approaches have been shown to promote health and lifespan in different models by targeting organismal or cell-specific processes (Gonzalez-Freire et al., 2020; Partridge et al., 2020). Immune cells are not an exception, and several studies highlighted the importance of metabolic alterations in immune cells during aging, as well as proposed ways to target this phenomenon. An approach that is gaining attention for its potential in increasing overall health-span and perhaps life-span is caloric restriction (CR), which involves a reduction in caloric intake or fasting. Indeed, CR increases life-span in most model organisms tested to date, also showing health benefits in primates (Madeo et al., 2019). CR exerts its anti-aging functions through several pathways, including mTOR inhibition, sirtuins activation and enhanced AMP kinase function, which in turn induces autophagy, a major deregulated process in aging (Barbosa et al., 2019; Cantó and Auwerx, 2011; Guarente, 2007). CR also attenuates the effect of age on immune cells in mice, particularly on NK cells and T lymphocytes (White et al., 2017). In addition, CR may be implicated in immune suppression, resulting in increased susceptibility to infections in fruit flies (Ayres and Schneider, 2009). A preliminary trial suggests this is not the case in humans (Meydani et al., 2016), however CR in humans remains poorly studied and more data is needed to delineate its benefits and risks for healthy aging.

From a therapeutic perspective, several agents that mimic the effect



of CR have been identified and tested successfully for their anti-aging effects (Madeo et al., 2019). At the center of attention is metformin, a drug approved for the treatment of type 2 diabetes with a still unclear mechanism of action, that includes the activation of AMPK, induction of autophagy and inhibition of mitochondrial respiration (Rena et al., 2017). Additionally, the intestinal microbiome has been identified as a target of metformin, which could in turn mediate its effect on aging through the modulation of pro- and anti-inflammatory factors (Cabreiro et al., 2013; Prattichizzo et al., 2018). Metformin is also able to increase the lifespan in *C. elegans* (Cabreiro et al., 2013) and in mice, both alone (Martin-Montalvo et al., 2013) and when administered in combination with rapamycin (Strong et al., 2016). Additionally, retrospective epidemiological studies correlated metformin treatment with reduced incidence of age-related diseases, such as cardiovascular diseases and cancer (Partridge et al., 2020), as well as with a reduction in all-cause mortality (Campbell et al., 2017). Metformin has been also used in combination with rhGH and DHEA in a small clinical trial to revert the epigenetic age of old healthy individuals. Notably, the treatment cocktail was able to induce thymus regeneration, changes in immune phenotype and reversal of the epigenetic age of the individuals, resulting in an increase predicted lifespan (Fahy et al., 2019). Due to the limited sample size, a follow-up trial (NCT04375657) with a bigger cohort is ongoing to assess the significance of the results.

Recently, it was reported that T cell mitochondrial dysfunction caused by the TFAM transcription factor deficiency promotes senescence in mice, inducing aging-related disorders and inflammaging (Desdín-Micó et al., 2020). While immunometabolism has been extensively studied in other contexts, such as cancer and autoimmune diseases, this is the first report directly linking metabolic alterations in immune cells to aging. Additionally, it was also reported that metformin exerts a positive effect on CD4 T cells from old individuals as a way to revert inflammaging. Strikingly, the increased autophagy and the normalized mitochondrial function induced by metformin on CD4<sup>+</sup> T cells switched the highly inflammatory elderly-derived T cells to a “young-like” phenotype (Bharath et al., 2020). A larger clinical trial, the Targeting Aging with METformin (TAME) initiative (<https://www.afar.org/tame-trial>), is predicted to start soon and recruit 3000 elderly to extensively test the benefits of metformin in aging and aging-related disease onset (Partridge et al., 2020).

Another well studied anti-aging drug target is mTORC1, a central protein in several metabolic pathways. Rapamycin, a specific mTORC1 inhibitor and CR mimicker, is able to increase longevity in various model organisms (Blagosklonny, 2019; Johnson et al., 2013). Among its effects, rapamycin is effective in restoring the HSC renewing capacities in old mice and in increasing influenza vaccination efficiency, reversing immunosenescence (Chen et al., 2009). An initial test in human volunteers revealed that the mTORC1 inhibitor RAD001 was able to reduce immunosenescence and improve the response to influenza vaccine (Mannick et al., 2014). Additionally, a clinical trial using a combination of the mTORC1 inhibitors RTB101 and RAD001, confirmed these findings showing enhanced immune function in old individuals, upregulated antiviral response and increased influenza vaccination efficiency (Mannick et al., 2018). However, despite the successful phase 2a and 2b clinical trials, the recent phase 3 trial with RTB101 was unsuccessful in enhancing immune functions in the elderly to reduce respiratory illnesses (Kaeberlein, 2020; Mannick et al., 2021). Further studies are planned to test rapamycin efficacy in reducing the clinical effects of aging and could help obtain data on immune-related effects (NCT04488601).

Another CR agent that is drawing interest is resveratrol, a natural polyphenolic compound of plant origin present in high quantities in berries and grapes (Baur and Sinclair, 2006). Resveratrol is able to increase lifespan in mice on a high-fat diet (Baur et al., 2006; Howitz et al., 2003). In nonhuman primates resveratrol reduces the inflammatory effects of high-fat diet and induces sirtuins expression (Mattison et al., 2014; Rajman et al., 2018). The anti-inflammatory effect of resveratrol

is mediated by its effect on several immune cells, including macrophages, T and B lymphocytes and NK cells by promoting immunomodulatory and anti-inflammatory cytokine production, as well as increasing Treg counts (Malaguamera, 2019). Another CR mimicking agent is the endogenous metabolite spermidine, a known inducer of autophagy that is able to increase lifespan in mice (Eisenberg et al., 2016). In addition, it was also demonstrated that administration of spermidine in mice is able to reduce B cell senescence (Zhang et al., 2019).

Finally, alpha-ketoglutarate, an endogenous metabolite, has a potent effect on the modulation of chronic inflammation. Indeed, its administration in old mice induces IL10 secretion from T cells, reducing morbidity and extending lifespan (Asadi Shahmirzadi et al., 2020).

All these reports indicate that immunometabolism is playing a central role in the aging of the immune system, and several drugs targeting various metabolic processes could hold a high therapeutic potential for immune rejuvenation strategies.

### 5.3. Targeting senescent cells

Senescent cells are characterized by cell cycle arrest, increased metabolic activity, upregulation of anti-apoptotic pathways and a senescence-associated secretory phenotype (SASP) that accumulate during aging in several tissues (Kirkland and Tchkonja, 2017). SASP includes production of several pro-inflammatory cytokines and chemokines that contribute to inflammaging and the development of age-related diseases (Coppé et al., 2008). Senolytic drugs specifically target senescent cells, therefore being a powerful tool to reduce both tissue-specific and systemic inflammation. Senescent cells are responsible for tissue aging and inflammation in young mice, and senolytics have been shown to improve health and increase lifespan in old mice (Xu et al., 2018). Additionally, the same senolytic cocktail was efficient in reducing senescent cell burden in a human clinical trial in individuals with diabetic kidney disease (Hickson et al., 2019). Several other senolytic agents, including HSP90 or BCL-2 and BCL-XL inhibitors, show promising results in mice and should be further investigated for their applicability and efficacy in humans (Fuhmann-Stroissnigg et al., 2017; He et al., 2020; Kirkland and Tchkonja, 2020).

While the age-mediated accumulation of senescent cells in many tissues is a widely accepted phenomenon, senescent immune cells have not been deeply characterized. Robust criteria for distinguishing senescent immune cells from highly differentiated but non-senescent immune cells remain unknown. Immune cells are known to express classical senescence markers, such as senescence-associated beta-galactosidase (SA-beta-gal) (Biran et al., 2017; Frasca et al., 2021; Hall et al., 2016; Rajagopalan and Long, 2012; Ye et al., 2012). Recently, an age-associated increase of SA-beta-gal activity was observed in all subsets of peripheral blood mononuclear (PBMC) cells, including T lymphocytes, plasmacytoid dendritic cells (pDCs), natural killer (NK) cells, monocytes, and B cells (Martínez-Zamudio et al., 2021). Strikingly, the number of CD8<sup>+</sup> T cells with a high level of SA-beta-gal activity in healthy subjects increases from 30 % in their 20 s to 64 % in their 60 s. Targeting senescent cells with a prodrug processed into a cytotoxic compound by  $\beta$ -gal has been proven to be extremely effective in reducing inflammation and restoring physical function in old mice (Cai et al., 2020). Notably, this effect was also partly mediated by depletion of SA-beta-gal positive macrophages from aged tissues (Cai et al., 2020). Comparing classical senescence markers such as SA-beta-gal with the immunological markers mentioned above might help define immune senescence and provide additional therapeutic options.

Additionally, it was recently reported the development of specific CAR-T cells directed against senescent cells expressing the plasminogen receptor uPAR on their surface (Amor et al., 2020). This opens the possibility to engineer T cells to recognize specific senescence-associated markers and create new senolytic approaches based on the CAR technology.

#### 5.4. Targeting immune epigenetics

Changes in the epigenetics state of cells have been defined as one of the hallmarks of aging and correlate with lifespan in several organisms (López-Otín et al., 2013). Notably, the DNA methylation state can be used to assess the biological age of the cell and this is claimed to be more accurate than any other method investigated, such as telomere length or other transcriptomic or proteomic biomarkers (Horvath and Raj, 2018; Jylhävä et al., 2017). In the immune compartment, epigenetics plays a pivotal role in mediating several processes such as lineage differentiation (Allan et al., 2012; Pace et al., 2018) and immune memory formation (Abdelsamed et al., 2018; Scharer et al., 2017). During aging, HSCs become globally hypomethylated, while at specific loci, such as the Polycomb Repressive Complex 2 binding sites and IL7R gene, there is hypermethylation (Beerman et al., 2013; Taiwo et al., 2013; Ucar et al., 2017). Other reports suggest the hypomethylation of FoxP3 leads to an increase in the number of Tregs in older mice (Garg et al., 2014). Also, chromatin modifications have been associated with aging. Indeed, increased H3K4me3 levels affects genes involved in HSCs identity and renewal, while overall H3K9me3 decrease leads to phenotypical changes in the HSCs compartment (Djegloul et al., 2016; Sun et al., 2014).

Another epigenetic driver of inflammaging has been identified in transposon activation. During aging, retrotransposable elements become transcriptionally active and promote IFN $\gamma$ -mediated inflammation, and their pharmacological repression reverses this phenotype in mice (De Cecco et al., 2019). Additionally, the derepression of these transposable elements is mediated by SIRT6 (Simon et al., 2019). This suggests that SIRT6 activating therapies might show anti-aging effects through the reduction of systemic inflammation by restoring epigenetic repression of retrotransposons.

While additional studies are needed to pinpoint the importance of


immune cells epigenetics in aging, it is clear that epigenetic changes have a prominent role in shaping the phenotype of the cells they are affecting (Jasiulionis, 2018; Keenan and Allan, 2019). Several epigenetic drugs have been developed in recent years to target epigenetic changes in different diseases and contexts (Ganesan et al., 2019). Investigating their effect in aging and particularly in the modulation of immunosenescence could add additional therapeutic approaches to the fight against aging, providing novel ways to rejuvenate the immune system.

#### 6. Future directions

Our understanding of immune alterations during aging is increasing exponentially. In the last few years, several new immune populations have been identified to drastically change during lifetime and influence each other and the overall immune competence of the organism. New anti-aging therapeutic approaches targeting specific immune dysfunctions in the elderly are being proposed at a growing pace, with many of them showing promising pre-clinical results (Table 1). While their clinical application and long-term safety remain to be proven in clinical trials, current evidence suggests that immune targeting approaches may revolutionize the longevity field. Due to its interconnection with all other systems in the body, its relevance for homeostasis maintenance and the primary role in fighting infections and cancer, the immune system represents the ideal target to comprehensively address many hallmarks of aging. For this reason, anti-aging immune targeting therapies could represent a potent approach for improving healthspan. The therapeutic strategies described in this review can be summarized as: I. Rejuvenating strategies to replenish aged immune tissues or cells (e.g., rejuvenation of the thymus and the HSCs compartment or young cell transfer) II. Immunosuppressive strategies to tune down dysregulated populations that promote inflammaging III. Immunostimulatory

**Table 1**  
Aging-related immune changes and reported therapeutic strategies.

Cell types	Alterations	References	Therapeutic approach	Species	References
HSCs	Reduced potency and myeloid skewing	Leins et al., 2018; Pang et al., 2011; Lee et al., 2019; Ju et al., 2007; Florian et al., 2018	p38 inhibition	Mouse	Ito et al., 2006; Jung et al., 2016
			cdc42 inhibition	Mouse	Leins et al., 2018; Florian et al., 2020
	Decreased number and activity	Goronzy and Weyand, 2019; Kityo et al., 2018; Ucar et al., 2017	HSCs transplant	Mouse	Kovina et al., 2019; Das et al., 2019; Yousefzadeh et al., 2021
T cells	Increased senescence	Pangrazzi and Weinberger, 2020; Covre et al., 2020; Lanna et al., 2017; Callender et al., 2018; Shirakawa et al., 2016	IL-7 administration	Human	Rosenberg et al., 2006, Y Lévy et al., 2012
			CD153 vaccination	Mouse	Yoshida et al., 2020
B cells	Decreased telomere length	Tedone et al., 2019; Huang et al., 2017; Pangrazzi and Weinberger, 2020	Sestrin inhibition	Mouse	Lanna et al., 2017; Pereira et al., 2020
			Increase in aging-promoting populations	Ratliff et al., 2013; Camell et al., 2019; Rodriguez-Zhurbenko et al., 2019	B cell depletion
NK cells	Reduced activity	Song et al., 2020; Gayoso et al., 2011; Almeida-Oliveira et al., 2011	IL-1R antagonists	Mouse	Camell et al., 2019
Thymocytes	Involution	Thomas et al., 2020; Rode et al., 2015; Sun et al., 2010	NKG2A blockade	Mouse/ Human	André et al., 2018; Kamiya et al., 2019; Pereira et al., 2019
			FOXN1 induction	Mouse	Sun et al., 2010; Kim et al., 2015)
Macrophages	Altered secretory activity and polarization	Stahl and Brown, 2015; Allavena et al., 2008; Clark et al., 2020	Thymus reconstitution	Mouse	Bredenkamp et al., 2014; Oh et al., 2020; Campinoti et al., 2020
			Increased p38 activity	De Maeyer et al., 2020	IL-2/CD40 therapy
DCs	Reduced cDC2 activity	Stebegg et al., 2020	p38 inhibition	Human	De Maeyer et al., 2020; Chambers et al., 2021
Granulocytes	Altered activity and inflammatory phenotype	Fulop et al., 2004; Frisch et al., 2019; Brigger et al., 2020	TLR agonists	Mouse	Stebegg et al., 2020
			Eosinophil transfer	Mouse	Brigger et al., 2020
Microglia	Increased inflammation	Rawji et al., 2016	Monophosphoryl lipid A	Mouse	Michaud et al., 2013
			PPAR $\alpha$ / $\gamma$ modulation	Mouse	Yamanaka et al., 2012
	Reduced activity	Pluvinage et al., 2019; Friedman et al., 2018	CD22 blockade	Mouse	Pluvinage et al., 2019



**Fig. 4.** Combining and balancing immune rejuvenation strategies. Rejuvenating strategies should combine both generalized and cell-specific approaches in order to have a balanced modification of the immune system. Immunostimulatory and immunosuppressive strategies can address different dysfunctional areas of the immune system and combine their effects towards a sustainable immune rejuvenation.

strategies to re-activate, eliminate, or replace senescent cells (Fig. 4). While some of the therapies in development target defined immune cell types or even specific subpopulations, other approaches are directed against general dysregulated processes that are common to many different cell types. Examples are metabolic or epigenetic targeting drugs that will affect multiple immune and non-immune cells, likely with distinct effects on their phenotype. When considering these treatments, it will be essential to assess the full spectra of effects, both in the cell type of interest and potential off-target effects.

Another aspect to consider is the strong differences between individuals, including at the level of heterogeneity of immune system changes with age. In several medical areas, treatments are now based on individual characteristics of the patient, thanks to multi-omics analysis that provide genetic and epigenomic personalized information. Precision medicine is now the standard approach for several types of cancers where treatments are decided based on the mutational profile of the patient (Friedman et al., 2015). In aging, distinct individuals respond differently to metformin, indicating that there might be specific genetic or epigenetic characteristic that can influence the treatment efficacy (Soukas et al., 2019). Stratification of the aged population based on biomarkers identified from multi-omics data could therefore define subgroups that might benefit from specific treatments and allow more effective personalized approaches.

The strong relevance of the immune system in aging therapy is reflected also by the flexibility of gene therapy and engineering of immune cells *ex vivo*. Because changes to the immune system will have systemic effects, *ex vivo* gene therapy of immune system cells has great potential as a therapy for aging. The development of CAR-T cells has already demonstrated its efficacy in cancer therapy (Singh and McGuirk, 2020) and autoimmune diseases (Ellebrecht et al., 2016; Kansal et al., 2019) and recent evidence suggest the potential application in aging and treatment of age-associated diseases (Amor et al., 2020). The flexibility of the CAR technology, potentially adaptable to any senescence marker, and the rise of other gene therapy approaches for stable T cells engineering (Bailey and Maus, 2019; Honaker et al., 2020) open new possibilities for a stable modification of the immune system to restore active immune surveillance and clearance of senescent and other dysfunctional cells.

Given the complexity of the immune system and aging, the biggest challenge for the years to come will be to find the right combination of the various therapeutic approaches described in this review and to identify the group of individuals that would benefit the most from each of them. Targeting multiple components of the immune system at once will require an extremely balanced approach to avoid undesired side effects. On the one hand, exaggerating immune suppression to reduce

inflammaging could result in an increased susceptibility to infections or loss of basic immune homeostatic functions. On the other hand, a strong stimulation of the immune system to re-gain its full functionality could result in an increased risk of autoimmune diseases or acute inflammatory side effects. To maintain the right balance in the immune system, rejuvenating approaches need to be fine-tuned to affect the right components without being detrimental on others (Fig.4). Personalized combinatorial approaches will allow different immunological processes to be affected leading to efficient and durable effects. Extensive pre-clinical and clinical studies are needed to define the approaches that will yield the best health outcomes with the least side effects, but given the large amount of targeting possibilities and the promising recent developments in the field, immune rejuvenation can already be considered a realistic biological milestone to be achieved in the near future.

#### Declaration of Competing Interest

Simone Borgoni, Ksenia S. Kudryashova, Ksenia Burka and João Pedro de Magalhães work/consult for Centaura AG, a company focused on development of radical anti-aging interventions.

#### Acknowledgements

The authors are grateful to Arne Akbar, Graham Pawelec, Tamas Fulop, Jerry Shay, Brian Kennedy, Vera Gorbunova, Andrei Seluanov, Joseph Zullo and Alina Chan for the useful discussions and comments on the manuscript. Figures were generated using Biorender.com

#### References

- Abdelsamed, H.A., Zebley, C.C., Youngblood, B., 2018. Epigenetic maintenance of acquired gene expression programs during memory CD8 T cell homeostasis. *Front. Immunol.* <https://doi.org/10.3389/fimmu.2018.00006>.
- Agrawal, S., Ganguly, S., Tran, A., Sundaram, P., Agrawal, A., 2016. Retinoic acid treated human dendritic cells induce T regulatory cells via the expression of CD141 and GARP which is impaired with age. *Aging (Albany, NY)* 8, 1223–1235. <https://doi.org/10.18632/aging.100973>.
- Agrawal, A., Agrawal, S., Gupta, S., 2018. Role of Dendritic Cells in Aging, in: *Handbook of Immunosenescence*. Springer International Publishing, pp. 1–15. [https://doi.org/10.1007/978-3-319-64597-1\\_25-1](https://doi.org/10.1007/978-3-319-64597-1_25-1).
- Ahadi, S., Zhou, W., Schüssler-Fiorenza Rose, S.M., Sailani, M.R., Contrepois, K., Avina, M., Ashland, M., Brunet, A., Snyder, M., 2020. Personal aging markers and ageotypes revealed by deep longitudinal profiling. *Nat. Med.* <https://doi.org/10.1038/s41591-019-0719-5>.
- Aiello, A., Farzaneh, F., Candore, G., Caruso, C., Davinelli, S., Gambino, C.M., Ligotti, M. E., Zareian, N., Accardi, G., 2019. Immunosenescence and its hallmarks: how to oppose aging strategically? A review of potential options for therapeutic intervention. *Front. Immunol.* <https://doi.org/10.3389/fimmu.2019.02247>.
- Allan, R.S., Zueva, E., Cammas, F., Schreiber, H.A., Masson, V., Belz, G.T., Roche, D., Maison, C., Quivy, J.P., Almouzni, G., Amigorena, S., 2012. An epigenetic silencing

- pathway controlling T helper 2 cell lineage commitment. *Nature* 487, 249–253. <https://doi.org/10.1038/nature11173>.
- Allavena, P., Sica, A., Garlanda, C., Mantovani, A., 2008. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. *Immunol. Rev.* <https://doi.org/10.1111/j.1600-065X.2008.00607.x>.
- Allsopp, R.C., Cheshier, S., Weissman, L.L., 2001. Telomere shortening accompanies increased cell cycle activity during serial transplantation of hematopoietic stem cells. *J. Exp. Med.* 193, 917–924. <https://doi.org/10.1084/jem.193.8.917>.
- Allsopp, R.C., Morin, G.B., DePinho, R., Harley, C.B., Weissman, L.L., 2003. Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. *Blood* 102, 517–520. <https://doi.org/10.1182/blood-2002-07-2334>.
- Almeida-Oliveira, A., Smith-Carvalho, M., Porto, L.C., Cardoso-Oliveira, J., Ribeiro, Ados S., Falcão, R.R., Abdelhay, E., Bouzas, L.F., Thuler, L.C.S., Ornellas, M.H., Diamond, H.R., 2011. Age-related changes in natural killer cell receptors from childhood through old age. *Hum. Immunol.* 72, 319–329. <https://doi.org/10.1016/j.humimm.2011.01.009>.
- Alpert, A., Pickman, Y., Leipold, M., Rosenberg-Hasson, Y., Ji, X., Gaujoux, R., Rabani, H., Starostvetsky, E., Kveler, K., Schaffert, S., Furman, D., Caspi, O., Rosenschein, U., Khatri, P., Dekker, C.L., Maecker, H.T., Davis, M.M., Shen-Orr, S.S., 2019. A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. *Nat. Med.* 25, 487–495. <https://doi.org/10.1038/s41591-019-0381-y>.
- Amor, C., Feucht, J., Leibold, J., Ho, Y.J., Zhu, C., Alonso-Curbelo, D., Mansilla-Soto, J., Boyer, J.A., Li, X., Giavridis, T., Kulick, A., Houlihan, S., Peerschke, E., Friedman, S. L., Ponomarev, V., Piersigilli, A., Sadelain, M., Lowe, S.W., 2020. Senolytic CAR T cells reverse senescence-associated pathologies. *Nature* 583, 127. <https://doi.org/10.1038/s41586-020-2403-9>.
- André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafant, C., Gauthier, L., Morel, A., Rossi, B., Remark, R., Bresó, V., Bonnet, E., Habif, G., Guia, S., Lalanne, A.L., Hoffmann, C., Lantz, O., Fayette, J., Boyer-Chammard, A., Zerbib, R., Dodion, P., Ghadially, H., Jure-Kunkel, M., Morel, Y., Herbst, R., Narni-Mancinelli, E., Cohen, R.B., Vivier, E., 2018. Anti-NKG2a mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. *Cell* 175, 1731–1743. <https://doi.org/10.1016/j.cell.2018.10.014> e13.
- Andrew, D., Aspinall, R., 2001. IL-7 and not stem cell factor reverses both the increase in apoptosis and the decline in thymopoiesis seen in aged mice. *J. Immunol.* 166, 1524–1530. <https://doi.org/10.4049/jimmunol.166.3.1524>.
- Asadi Shahmirzadi, A., Edgar, D., Liao, C.Y., Hsu, Y.M., Lucanic, M., Asadi Shahmirzadi, A., Wiley, C.D., Gan, G., Kim, D.E., Kasler, H.G., Kuehnemann, C., Kaplowitz, B., Bhaumik, D., Riley, R.R., Kennedy, B.K., Lithgow, G.J., 2020. Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice. *Cell Metab.* 32, 447–456. <https://doi.org/10.1016/j.cmet.2020.08.004> e6.
- Avivi, I., Zisman-Rozen, S., Naor, S., Dai, I., Benhamou, D., Shahaf, G., Tabibian-Keissar, H., Rosenthal, N., Rakovsky, A., Hanna, A., Shechter, A., Peled, E., Benyamini, N., Dmitrukha, E., Barshack, I., Mehr, R., Melamed, D., 2019. Depletion of B cells rejuvenates the peripheral B-cell compartment but is insufficient to restore immune competence in aging. *Aging Cell* 18. <https://doi.org/10.1111/acel.12959>.
- Aw, D., Silva, A.B., Palmer, D.B., 2007. Immunosenescence: emerging challenges for an aging population. *Immunology*. <https://doi.org/10.1111/j.1365-2567.2007.02555.x>.
- Ayres, J.S., Schneider, D.S., 2009. The role of anorexia in resistance and tolerance to infections in *Drosophila*. *PLoS Biol.* 7, 1000150. <https://doi.org/10.1371/journal.pbio.1000150>.
- Bailey, S.R., Maus, M.V., 2019. Gene editing for immune cell therapies. *Nat. Biotechnol.* <https://doi.org/10.1038/s41587-019-0137-8>.
- Bär, C., Povedano, J.M., Serrano, R., Benitez-Buelga, C., Popkes, M., Formentini, I., Bobadilla, M., Bosch, F., Blasco, M.A., 2016. Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia. *Blood* 127, 1770–1779. <https://doi.org/10.1182/blood-2015-08-667485>.
- Barbé-Tuana, F., Funchal, G., Schmitz, C.R.R., Maurmann, R.M., Bauer, M.E., 2020. The interplay between immunosenescence and age-related diseases. *Semin. Immunopathol.* <https://doi.org/10.1007/s00281-020-00806-z>.
- Barbosa, M.C., Grosso, R.A., Fader, C.M., 2019. Hallmarks of aging: an autophagic perspective. *Front. Endocrinol. (Lausanne)*. <https://doi.org/10.3389/fendo.2018.00790>.
- Barzilay, N., Huffman, D.M., Muzumdar, R.H., Bartke, A., 2012. The critical role of metabolic pathways in aging. *Diabetes*. <https://doi.org/10.2337/db11-1300>.
- Baur, J.A., Sinclair, D.A., 2006. Therapeutic potential of resveratrol: the in vivo evidence. *Nat. Rev. Drug Discov.* <https://doi.org/10.1038/nrd2060>.
- Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., Prabhu, V.V., Allard, J.S., Lopez-Lluch, G., Lewis, K., Pistell, P.J., Poosala, S., Becker, K.G., Boss, O., Gwinn, D., Wang, M., Ramaswamy, S., Fishbein, K.W., Spencer, R.G., Lakatta, E.G., Le Couteur, D., Shaw, R.J., Navas, P., Puigserver, P., Ingram, D.K., De Cabo, R., Sinclair, D.A., 2006. Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* 444, 337–342. <https://doi.org/10.1038/nature05354>.
- Beerman, I., Bock, C., Garrison, B.S., Smith, Z.D., Gu, H., Meissner, A., Rossi, D.J., 2013. Proliferation-dependent alterations of the DNA methylation landscape underlie hematopoietic stem cell aging. *Cell Stem Cell* 12, 413–425. <https://doi.org/10.1016/j.stem.2013.01.017>.
- Bharath, L.P., Agrawal, M., McCambridge, G., Nicholas, D.A., Hasturk, H., Liu, J., Jiang, K., Liu, R., Guo, Z., Deeney, J., Apovian, C.M., Snyder-Cappione, J., Hawk, G. S., Fleeman, R.M., Pihl, R.M.F., Thompson, K., Belkina, A.C., Cui, L., Proctor, E.A., Kern, P.A., Nikolajczyk, B.S., 2020. Metformin enhances autophagy and normalizes mitochondrial function to alleviate aging-associated inflammation. *Cell Metab.* 32, 44–55. <https://doi.org/10.1016/j.cmet.2020.04.015> e6.
- Biran, A., Zada, L., Abou Karam, P., Vadai, E., Roitman, L., Ovadya, Y., Porat, Z., Krizhanovsky, V., 2017. Quantitative identification of senescent cells in aging and disease. *Aging Cell* 16, 661–671. <https://doi.org/10.1111/acel.12592>.
- Blagosklonny, M.V., 2019. Rapamycin for longevity: opinion article. *Aging (Albany, NY)* 11, 8048–8067. <https://doi.org/10.18632/aging.102355>.
- Borrego, F., Alonso, M.C., Galiani, M.D., Carracedo, J., Ramirez, R., Ostos, B., Peña, J., Solana, R., 1999. NK phenotypic markers and IL2 response in NK cells from elderly people. *Exp. Gerontol.* 34, 253–265. [https://doi.org/10.1016/S0531-5565\(98\)00076-X](https://doi.org/10.1016/S0531-5565(98)00076-X).
- Bredenkamp, N., Ulyanchenko, S., O'Neill, K.E., Manley, N.R., Vaidya, H.J., Blackburn, C.C., 2014. An organized and functional thymus generated from FOXN1-reprogrammed fibroblasts. *Nat. Cell Biol.* 16, 902–908. <https://doi.org/10.1038/ncb3023>.
- Brigger, D., Riether, C., van Brummelen, R., Mosher, K.I., Shiu, A., Ding, Z., Zbären, N., Gasser, P., Guntern, P., Yousef, H., Castellano, J.M., Storni, F., Graff-Radford, N., Britschgi, M., Grandgirard, D., Hinterbrandner, M., Siegrist, M., Moullan, N., Hofstetter, W., Leib, S.L., Villiger, P.M., Auwerx, J., Villeda, S.A., Wyss-Coray, T., Noti, M., Eggel, A., 2020. Eosinophils regulate adipose tissue inflammation and sustain physical and immunological fitness in old age. *Nat. Metab.* 1–15. <https://doi.org/10.1038/s42255-020-0228-3>.
- Brown, K., Xie, S., Qiu, X., Mohrin, M., Shin, J., Liu, Y., Zhang, D., Scadden, D.T., Chen, D., 2013. SIRT3 reverses aging-associated degeneration. *Cell Rep.* 3, 319–327. <https://doi.org/10.1016/j.celrep.2013.01.005>.
- Cabreiro, F., Au, C., Leung, K.Y., Vergara-Irigaray, N., Cochemé, H.M., Noori, T., Weinkove, D., Schuster, E., Greene, N.D.E., Gems, D., 2013. Metformin retards aging in *C. Elegans* by altering microbial flora and methionine metabolism. *Cell* 153, 228–239. <https://doi.org/10.1016/j.cell.2013.02.035>.
- Cai, Y., Zhou, H., Zhu, Y., Sun, Q., Ji, Y., Xue, A., Wang, Y., Chen, W., Yu, X., Wang, L., Chen, H., Li, C., Luo, T., Deng, H., 2020. Elimination of senescent cells by  $\beta$ -galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. *Cell Res.* 30, 574–589. <https://doi.org/10.1038/s41422-020-0314-9>.
- Callender, L.A., Carroll, E.C., Beal, R.W.J., Chambers, E.S., Nourshargh, S., Akbar, A.N., Henson, S.M., 2018. Human CD8<sup>+</sup> EMRA T cells display a senescence-associated secretory phenotype regulated by p38 MAPK. *Aging Cell* 17, e12675. <https://doi.org/10.1111/acel.12675>.
- Camell, C.D., Günther, P., Lee, A., Goldberg, E.L., Spadaro, O., Youm, Y.H., Bartke, A., Hubbard, G.B., Ikeno, Y., Ruddle, N.H., Schultze, J., Dixit, V.D., 2019. Aging induces an Nlrp3 inflammasome-dependent expansion of adipose B cells that impairs metabolic homeostasis. *Cell Metab.* 30, 1024–1039. <https://doi.org/10.1016/j.cmet.2019.10.006> e6.
- Camous, Xavier, Pera, Alejandra, Solana, Rafael, Larbi, Anis, 2012. NK cells in healthy aging and age-associated diseases - PubMed. *J. Biomed. Biotechnol.*
- Campbell, J.M., Bellman, S.M., Stephenson, M.D., Lisy, K., 2017. Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: a systematic review and meta-analysis. *Ageing Res. Rev.* <https://doi.org/10.1016/j.arr.2017.08.003>.
- Campinoti, S., Gjinovci, A., Ragazzini, R., Zanieri, L., Ariza-McNaughton, L., Catucci, M., Boeing, S., Park, J.E., Hutchinson, J.C., Muñoz-Ruiz, M., Manti, P.G., Vozza, G., Villa, C.E., Phylactopoulos, D.E., Maurer, C., Testa, G., Stauss, H.J., Teichmann, S.A., Sebire, N.J., Hayday, A.C., Bonnet, D., Bonfanti, P., 2020. Reconstitution of a functional human thymus by postnatal stromal progenitor cells and natural whole-organ scaffolds. *Nat. Commun.* 11. <https://doi.org/10.1038/s41467-020-20082-7>.
- Cancro, M.P., 2020. Age-associated B cells. *Annu. Rev. Immunol.* 38, 315–340. <https://doi.org/10.1146/annurev-immunol-092419-031130>.
- Cantó, C., Auwerx, J., 2011. Calorie restriction: Is AMPK a key sensor and effector? *Physiology*. <https://doi.org/10.1152/physiol.00010.2011>.
- Chaker, D., Mouawad, C., Azar, A., Quilliot, D., Achkar, I., Fajloun, Z., Makdissy, N., 2018. Inhibition of the RhoGTPase Cdc42 by ML141 enhances hepatocyte differentiation from human adipose-derived mesenchymal stem cells via the Wnt5a/P13K/miR-122 pathway: impact of the age of the donor. *Stem Cell Res. Ther.* 9, 167. <https://doi.org/10.1186/s13287-018-0910-5>.
- Chambers, E.S., Vukmanovic-Stejic, M., Shih, B.B., Trahair, H., Subramanian, P., Devine, O.P., Glanville, J., Gilroy, D., Rustin, M.H.A., Freeman, T.C., Mabbott, N.A., Akbar, A.N., 2021. Recruitment of inflammatory monocytes by senescent fibroblasts inhibits antigen-specific tissue immunity during human aging. *Nat. Aging* 1, 101–113. <https://doi.org/10.1038/s43587-020-00010-6>.
- Chen, C., Liu, Y., Liu, Y., Zheng, P., 2009. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. *Sci. Signal.* 2. <https://doi.org/10.1126/scisignal.2000559> ra75-ra75.
- Chu, Y.W., Schmitz, S., Choudhury, B., Telford, W., Kapoor, V., Garfield, S., Howe, D., Gress, R.E., 2008. Exogenous insulin-like growth factor 1 enhances thymopoiesis predominantly through thymic epithelial cell expansion. *Blood* 112, 2836–2846. <https://doi.org/10.1182/blood-2008-04-149435>.
- Clark, D., Brazina, S., Yang, F., Hu, D., Hsieh, C.L., Niemi, E.C., Miclau, T., Nakamura, M. C., Marcuro, R., 2020. Age-related changes to macrophages are detrimental to fracture healing in mice. *Aging Cell* 19. <https://doi.org/10.1111/acel.13112>.
- Coakley, J.D., Breen, E.P., Moreno-Olivera, A., Al-Harbi, A.I., Melo, A.M., O'Connell, B., McManus, R., Doherty, D.G., Ryan, T., 2019. Dysregulated T helper type 1 (Th1) and Th17 responses in elderly hospitalised patients with infection and sepsis. *PLoS One* 14, e0224276. <https://doi.org/10.1371/journal.pone.0224276>.
- Coppé, J.-P., Patil, C.K., Rodier, F., Sun, Y., Muñoz, D.P., Goldstein, J., Nelson, P.S., Desprez, P.-Y., Campisi, J., 2008. Senescence-associated secretory phenotypes reveal

- cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. *PLoS Biol.* 6, e301. <https://doi.org/10.1371/journal.pbio.0060301>.
- Covre, L.P., De Maeyer, R.P.H., Gomes, D.C.O., Akbar, A.N., 2020. The role of senescent T cells in immunopathology. *Aging Cell*. <https://doi.org/10.1111/acel.13272>.
- Cunha, L.L., Perazzio, S.F., Azzi, J., Cravedi, P., Riella, L.V., 2020. Remodeling of the immune response with aging: immunosenescence and its potential impact on COVID-19 immune response. *Front. Immunol.* 11, 1748. <https://doi.org/10.3389/fimmu.2020.01748>.
- Das, M.M., Godoy, M., Chen, S., Moser, V.A., Avalos, P., Roxas, K.M., Dang, I., Yáñez, A., Zhang, W., Bresee, C., Arditi, M., Liu, G.Y., Svendsen, C.N., Goodridge, H.S., 2019. Young bone marrow transplantation preserves learning and memory in old mice. *Commun. Biol.* 2, 1–10. <https://doi.org/10.1038/s42003-019-0298-5>.
- De Cecco, M., Ito, T., Petrashen, A.P., Elias, A.E., Skvir, N.J., Criscione, S.W., Caligiana, A., Broccoli, G., Adney, E.M., Boeke, J.D., Le, O., Beauséjour, C., Ambati, J., Ambati, K., Simon, M., Seluanov, A., Gorbunova, V., Slagboom, P.E., Helfand, S.L., Neretti, N., Sedivy, J.M., 2019. L1 drives IFN in senescent cells and promotes age-associated inflammation. *Nature* 566, 73–78. <https://doi.org/10.1038/s41586-018-0784-9>.
- De Haan, G., Lazare, S.S., 2018. Aging of hematopoietic stem cells. *Blood*. <https://doi.org/10.1182/blood-2017-06-746412>.
- De Maeyer, R.P.H., van de Merwe, R.C., Louie, R., Bracken, O.V., Devine, O.P., Goldstein, D.R., Uddin, M., Akbar, A.N., Gilroy, D.W., 2020. Blocking elevated p38 MAPK restores efferocytosis and inflammatory resolution in the elderly. *Nat. Immunol.* 21, 615–625. <https://doi.org/10.1038/s41590-020-0646-0>.
- De Magalhães, J.P., 2013. How ageing processes influence cancer. *Nat. Rev. Cancer*. <https://doi.org/10.1038/nrc3497>.
- Desdín-Micó, G., Soto-Herederó, G., Aranda, J.F., Oller, J., Carrasco, E., Gabandé-Rodríguez, E., Blanco, E.M., Alfranca, A., Cussó, L., Desco, M., Ibañez, B., Gortazar, A.R., Fernández-Marcos, P., Navarro, M.N., Hernaez, B., Alcami, A., Baixauli, F., Mittelbrunn, M., 2020. T cells with dysfunctional mitochondria induce multimorbidity and premature senescence. *Science* (80-) 368, 1371–1376. <https://doi.org/10.1126/science.aax0860>.
- Dillon, S.M., Liu, J., Purba, C.M., Christians, A.J., Kibbie, J.J., Castleman, M.J., McCarter, M.D., Wilson, C.C., 2020. Age-related alterations in human gut CD4 T cell phenotype, T helper cell frequencies, and functional responses to enteric bacteria. *J. Leukoc. Biol.* 107, 119–132. <https://doi.org/10.1002/JLB.5A0919-177RR>.
- Djehglouh, D., Kuranda, K., Kuzniak, I., Barbieri, D., Naguibneva, I., Choisy, C., Bories, J.C., Dosquet, C., Pla, M., Vanneau, V., Socié, G., Porteu, F., Garrick, D., Goodhardt, M., 2016. Age-associated decrease of the histone methyltransferase SUV39H1 in HSC perturbs heterochromatin and B lymphoid differentiation. *Stem Cell Rep.* 6, 970–984. <https://doi.org/10.1016/j.stemcr.2016.05.007>.
- Domingues, R., Lippi, A., Setz, C., Outeiro, T.F., Krisko, A., 2020. SARS-CoV-2, immunosenescence and inflammaging: partners in the COVID-19 crime. *Aging (Albany, NY)*. <https://doi.org/10.18632/aging.103989>.
- Dong, S., Wang, Q., Kao, Y.-R., Diaz, A., Tasset, I., Kaushik, S., Thiruthuvanathan, V., Zintiridou, A., Nieves, E., Dzieciatkowska, M., Reisz, J.A., Gavathiotis, E., D'Alessandro, A., Will, B., Cuervo, A.M., 2021. Chaperone-mediated autophagy sustains hematopoietic stem-cell function. *Nature* 1–7. <https://doi.org/10.1038/s41586-020-03129-z>.
- Dykstra, B., Olthof, S., Schreuder, J., Ritsema, M., De Haan, G., 2011. Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells. *J. Exp. Med.* 208, 2691–2703. <https://doi.org/10.1084/jem.20111490>.
- Eisenberg, T., Abdellatif, M., Schroeder, S., Primmessing, U., Stekovic, S., Pendl, T., Harger, A., Schipke, J., Zimmermann, A., Schmidt, A., Tong, M., Ruckentuhl, C., Dammbrueck, C., Gross, A.S., Herbst, V., Magnes, C., Trausinger, G., Narath, S., Meinitzer, A., Hu, Z., Kirsch, A., Eller, K., Carmona-Gutierrez, D., Büttner, S., Pietrocola, F., Knittelfelder, O., Schrepfer, E., Rockenfeller, P., Simonini, C., Rahn, A., Horsch, M., Moreth, K., Beckers, J., Fuchs, H., Gailus-Durner, V., Neff, F., Janik, D., Rathkolb, B., Rozman, J., De Angelis, M.H., Moustafa, T., Haemmerle, G., Mayr, M., Willeit, P., Von Frieling-Salewsky, M., Pieske, B., Scorrano, L., Pieber, T., Pechlaner, R., Willeit, J., Sigrist, S.J., Linke, W.A., Mühlfeld, C., Sadoshima, J., Dengjel, J., Kiechl, S., Kroemer, G., Sedej, S., Madeo, F., 2016. Cardioprotection and lifespan extension by the natural polyamine spermidine. *Nat. Med.* 22, 1428–1438. <https://doi.org/10.1038/nm.4222>.
- Ellebrecht, C.T., Bhoj, V.G., Nace, A., Choi, E.J., Mao, X., Cho, M.J., Di Zenzo, G., Lanzavecchia, A., Seykora, J.T., Cotsarelis, G., Milone, M.C., Payne, A.S., 2016. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. *Science* (80-) 353, 179–184. <https://doi.org/10.1126/science.aaf6756>.
- Elyahu, Y., Hekselman, I., Eizenberg-Magar, I., Berner, O., Strominger, I., Schiller, M., Mittal, K., Nemirovsky, A., Eremenko, E., Vital, A., Simonovsky, E., Chalifa-Caspi, V., Friedman, N., Yeger-Lotem, E., Monsonego, A., 2019. Aging promotes reorganization of the CD4 T cell landscape toward extreme regulatory and effector phenotypes. *Sci. Adv.* 5 <https://doi.org/10.1126/sciadv.aaw8330> eaaw8330.
- Fabbiano, S., Suá Rez-Zamorano, N., Rigo, D.E., Veyrat-Durebex, C., Döck, A.S., Collin, D.J., Correspondence, M.T., Trajkovski, M., 2016. Caloric restriction leads to Browning of white adipose tissue through type 2 immune signaling article caloric restriction leads to Browning of white adipose tissue through type 2 immune signaling. *Cell Metab.* 24, 434–446. <https://doi.org/10.1016/j.cmet.2016.07.023>.
- Fahy, G.M., Brooke, R.T., Watson, J.P., Good, Z., Vasanawala, S.S., Maecker, H., Leipold, M.D., Lin, D.T.S., Kober, M.S., Horvath, S., 2019. Reversal of epigenetic aging and immunosenescent trends in humans. *Aging Cell* 18. <https://doi.org/10.1111/acel.13028>.
- Fane, M., Weeraratna, A.T., 2020. How the ageing microenvironment influences tumour progression. *Nat. Rev. Cancer*. <https://doi.org/10.1038/s41568-019-0222-9>.
- Florian, M.C., Nattamai, K.J., Dörr, K., Marka, G., Überle, B., Vas, V., Eckl, C., Andrä, I., Schiemann, M., Oostendorp, R.A.J., Scharffetter-Kochanek, K., Kestler, H.A., Zheng, Y., Geiger, H., 2013. A canonical to non-canonical Wnt signalling switch in haematopoietic stem-cell ageing. *Nature* 503, 392–396. <https://doi.org/10.1038/nature12631>.
- Florian, M.C., Klose, M., Sacma, M., Jablanovic, J., Knudson, L., Nattamai, K.J., Marka, G., Vollmer, A., Soller, K., Sakk, V., Cabezas-Wallscheid, N., Zheng, Y., Mulaw, M.A., Glauche, I., Geiger, H., 2018. Aging alters the epigenetic asymmetry of HSC division. *PLoS Biol.* 16 <https://doi.org/10.1371/journal.pbio.2003389>.
- Florian, M.C., Leins, H., Gobs, M., Han, Y., Marka, G., Soller, K., Vollmer, A., Sakk, V., Nattamai, K.J., Rayes, A., Zhao, X., Setchell, K., Mulaw, M., Wagner, W., Zheng, Y., Geiger, H., 2020. Inhibition of Cdc42 activity extends lifespan and decreases circulating inflammatory cytokines in aged female C57BL/6 mice. *Aging Cell*. <https://doi.org/10.1111/acel.13208>.
- Franceschi, C., Bonafe, M., Valensin, S., Olivieri, F., De Luca, M., Ottaviani, E., De Benedictis, G., 2000. Inflamm-aging. An evolutionary perspective on immunosenescence, in: *annals of the New York Academy of Sciences*. New York Acad. Sci. 244–254. <https://doi.org/10.1111/j.1749-6632.2000.tb06651.x>.
- Frasca, D., Romero, M., Diaz, A., Garcia, D., Thaller, S., Blomberg, B.B., 2021. B cells with a senescent-associated secretory phenotype accumulate in the adipose tissue of individuals with obesity. *Int. J. Mol. Sci.* 22, 1–11. <https://doi.org/10.3390/ijms22041839>.
- Friedman, A.A., Letai, A., Fisher, D.E., Flaherty, K.T., 2015. Precision medicine for cancer with next-generation functional diagnostics. *Nat. Rev. Cancer*. <https://doi.org/10.1038/nrc4015>.
- Friedman, B.A., Srinivasan, K., Ayalon, G., Meilandt, W.J., Lin, H., Huntley, M.A., Cao, Y., Lee, S.H., Haddick, P.C.G., Ngu, H., Modrusan, Z., Larson, J.L., Kaminker, J. S., van der Brug, M.P., Hansen, D.V., 2018. Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer's disease not evident in mouse models. *Cell Rep.* 22, 832–847. <https://doi.org/10.1016/j.celrep.2017.12.066>.
- Frisch, B.J., Hoffman, C.M., Latchney, S.E., LaMere, M.W., Myers, J., Ashton, J., Li, A.J., Saunders, J., Palis, J., Perkins, A.S., McCabe, A., Smith, J.N.P., McGrath, K.E., Rivera-Escalera, F., McDavid, A., Liesveld, J.L., Korshunov, V.A., Elliott, M.R., MacNamara, K.C., Becker, M.W., Calvi, L.M., 2019. Aged marrow macrophages expand platelet-biased hematopoietic stem cells via interleukin-1B. *JCI Insight* 4. <https://doi.org/10.1172/jci.insight.124213>.
- Fry, T.J., Mackall, C.L., 2005. The many faces of IL-7: from Lymphopoiesis to peripheral T cell maintenance. *J. Immunol.* 174, 6571–6576. <https://doi.org/10.4049/jimmunol.174.11.6571>.
- Fuhrmann-Stroissnigg, H., Ling, Y.Y., Zhao, J., McGowan, S.J., Zhu, Y., Brooks, R.W., Grassi, D., Gregg, S.Q., Stripay, J.L., Dorronsoro, A., Corbo, L., Tang, P., Bukata, C., Ring, N., Giacca, M., Li, X., Tchkonina, T., Kirkland, J.L., Niedernhofer, L.J., Robbins, P.D., 2017. Identification of HSP90 inhibitors as a novel class of senolytics. *Nat. Commun.* 8 <https://doi.org/10.1038/s41467-017-00314-z>.
- Fulop, T., Larbi, A., Douzich, N., Fortin, C., Guérard, K.P., Lesur, O., Khalil, A., Dupuis, G., 2004. Signal transduction and functional changes in neutrophils with aging. *Aging Cell*. <https://doi.org/10.1111/j.1474-9728.2004.00110.x>.
- Fulop, T., Larbi, A., Dupuis, G., Le Page, A., Frost, E.H., Cohen, A.A., Witkowski, J.M., Franceschi, C., 2018. Immunosenescence and inflamm-aging As two sides of the same coin: friends or foes? *Front. Immunol.* 8, 1960. <https://doi.org/10.3389/fimmu.2017.01960>.
- Ganesan, A., Arimondo, P.B., Rots, M.G., Jeronimo, C., Berdasco, M., 2019. The timeline of epigenetic drug discovery: from reality to dreams. *Clin. Epigenetics*. <https://doi.org/10.1186/s13148-019-0776-0>.
- Garg, S.K., Delaney, C., Toubai, T., Ghosh, A., Reddy, P., Banerjee, R., Yung, R., 2014. Aging is associated with increased regulatory T-cell function. *Aging Cell* 13, 441–448. <https://doi.org/10.1111/acel.12191>.
- Gayoso, I., Sanchez-Correa, B., Campos, C., Alonso, C., Pera, A., Casado, J.G., Morgado, S., Tarazona, R., Solana, R., 2011. Immunosenescence of human natural killer cells. *J. Innate Immun.* 3, 337–343. <https://doi.org/10.1159/000328005>.
- Gonzalez-Freire, M., Diaz-Ruiz, A., Hauser, D., Martinez-Romero, J., Ferrucci, L., Bernier, M., de Cabo, R., 2020. The road ahead for health and lifespan interventions. *Ageing Res. Rev.* <https://doi.org/10.1016/j.arr.2020.101037>.
- Goronzy, J.J., Weyand, C.M., 2019. Mechanisms underlying T cell ageing. *Nat. Rev. Immunol.* <https://doi.org/10.1038/s41577-019-0180-1>.
- Gounder, S.S., Abdullah, B.J.J., Radzuan, N.E.I.B.M., Zain, F.D.B.M., Sait, N.B.M., Chua, C., Subramani, B., 2018. Effect of aging on NK cell population and their proliferation at ex vivo culture condition. *Anal. Cell. Pathol. (Amst)* 2018. <https://doi.org/10.1155/2018/7871814>.
- Guarente, L., 2007. Sirtuins in Aging and Disease, in: *Cold Spring Harbor Symposia on Quantitative Biology*. Cold Spring Harb Symp Quant Biol, pp. 483–488. <https://doi.org/10.1101/sqb.2007.72.024>.
- Guo, Z., Wang, G., Wu, B., Chou, W.C., Cheng, L., Zhou, C., Lou, J., Wu, D., Su, L., Zheng, J., Ting, J.P.Y., Wan, Y.Y., 2020. DCAF1 regulates Treg senescence via the ROS axis during immunological aging. *J. Clin. Invest.* 130, 5893–5908. <https://doi.org/10.1172/JCI136466>.
- Hadrup, S.R., Strindhall, J., Kollgaard, T., Seremet, T., Johansson, B., Pawelec, G., thor Straten, P., Wikby, A., 2006. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. *J. Immunol.* 176, 2645–2653. <https://doi.org/10.4049/jimmunol.176.4.2645>.
- Hall, B.M., Balan, V., Gleiberman, A.S., Strom, E., Krasnov, P., Virtuoso, L.P., Rydkina, E., Vujic, S., Balan, K., Gitlin, I., Leonova, K., Polinsky, A., Chernova, O.B., Gudkov, A. V., 2016. Aging of mice is associated with p16 (Ink4a)- and  $\beta$ -galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells. *Aging (Albany, NY)* 8, 1294–1315. <https://doi.org/10.18632/aging.100991>.

- Hammad, H., Lambrecht, B.N., 2008. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. *Nat. Rev. Immunol.* <https://doi.org/10.1038/nri2275>.
- He, Y., Zhang, X., Chang, J., Kim, H.N., Zhang, P., Wang, Y., Khan, S., Liu, X., Zhang, X., Lv, D., Song, L., Li, W., Thummuri, D., Yuan, Y., Wiegand, J.S., Ortiz, Y.T., Budamagunta, V., Elisseeff, J.H., Campisi, J., Almeida, M., Zheng, G., Zhou, D., 2020. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. *Nat. Commun.* 11 <https://doi.org/10.1038/s41467-020-15838-0>.
- Henson, S.M., Snelgrove, R., Hussell, T., Wells, D.J., Aspinall, R., 2005. An IL-7 fusion protein that shows increased thymopoietic ability. *J. Immunol.* 175, 4112–4118. <https://doi.org/10.4049/jimmunol.175.6.4112>.
- Henson, S.M., Lanna, A., Riddell, N.E., Franzese, O., Macaulay, R., Griffiths, S.J., Puleston, D.J., Watson, A.S., Simon, A.K., Tooze, S.A., Akbar, A.N., 2014. P38 signaling inhibits mTORC1-independent autophagy in senescent human CD8+ T cells. *J. Clin. Invest.* 124, 4004–4016. <https://doi.org/10.1172/JCI75051>.
- Herrero, C., Sebastiaán, C., Marqués, L., Comalada, M., Xaus, J., Valledor, A.F., Lloberas, J., Celada, A., 2002. Immunosenescence of macrophages: reduced MHC class II gene expression. *Exp. Gerontol.* 37, 389–394. [https://doi.org/10.1016/S0531-5565\(01\)00205-4](https://doi.org/10.1016/S0531-5565(01)00205-4).
- Hickson, L.T.J., Langhi Prata, L.G.P., Bobart, S.A., Evans, T.K., Giorgadze, N., Hashmi, S. K., Herrmann, S.M., Jensen, M.D., Jia, Q., Jordan, K.L., Kellogg, T.A., Khosla, S., Koerber, D.M., Lagnado, A.B., Lawson, D.K., LeBrasseur, N.K., Lerman, L.O., McDonald, K.M., McKenzie, T.J., Passos, J.F., Pignolo, R.J., Pirtskhalava, T., Saadiq, I.M., Schaefer, K.K., Textor, S.C., Victorelli, S.G., Volkman, T.L., Xue, A., Wentworth, M.A., Wissler Gerdes, E.O., Zhu, Y., Tchkonja, T., Kirkland, J.L., 2019. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. *EBioMed.* 47, 446–456. <https://doi.org/10.1016/j.ebiom.2019.08.069>.
- Holodick, N.E., Rothstein, T.L., 2015. B cells in the aging immune system: time to consider B-1 cells. *Ann. N. Y. Acad. Sci.* 1362, 176–187. <https://doi.org/10.1111/nyas.12825>.
- Honaker, Y., Hubbard, N., Xiang, Y., Fisher, L., Hagin, D., Sommer, K., Song, Y., Yang, S. J., Lopez, C., Tappen, T., Dam, E.M., Khan, I., Hale, M., Buckner, J.H., Scharenberg, A.M., Torgerson, T.R., Rawlings, D.J., 2020. Gene editing to induce FOXp3 expression in human CD4+ T cells leads to a stable regulatory phenotype and function. *Sci. Transl. Med.* 12 <https://doi.org/10.1126/scitranslmed.aay6422>.
- Horvath, S., Raj, K., 2018. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. *Nat. Rev. Genet.* <https://doi.org/10.1038/s41576-018-0004-3>.
- Hosokawa, K., MacArthur, B.D., Ikushima, Y.M., Toyama, H., Masuhiro, Y., Hanazawa, S., Suda, T., Arai, F., 2017. The telomere binding protein Pot1 maintains haematopoietic stem cell activity with age. *Nat. Commun.* 8 <https://doi.org/10.1038/s41467-017-00935-4>.
- Howitz, K.T., Bitterman, K.J., Cohen, H.Y., Lamming, D.W., Lavu, S., Wood, J.G., Zipkin, R.E., Chung, P., Kisilewski, A., Zhang, L.L., Scherer, B., Sinclair, D.A., 2003. Small molecule activators of sirtuins extend *Saccharomyces cerevisiae* lifespan. *Nature* 425, 191–196. <https://doi.org/10.1038/nature01960>.
- Hsieh, C.C., Papaconstantinou, J., 2002. The effect of aging on p38 signaling pathway activity in the mouse liver and in response to ROS generated by 3-nitropropionic acid. *Mech. Ageing Dev.* 123, 1423–1435. [https://doi.org/10.1016/S0047-6374\(02\)00084-2](https://doi.org/10.1016/S0047-6374(02)00084-2).
- Huang, E., Tedone, E., O'Hara, R., Cornelius, C., Lai, T.P., Ludlow, A., Wright, W.E., Shay, J.W., 2017. The maintenance of telomere length in CD28+ t cells during T lymphocyte stimulation. *Sci. Rep.* 7 <https://doi.org/10.1038/s41598-017-05174-7>.
- Ito, K., Hirao, A., Arai, F., Takubo, K., Matsuoka, S., Miyamoto, K., Ohmura, M., Naka, K., Hosokawa, K., Ikeda, Y., Suda, T., 2006. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. *Nat. Med.* 12, 446–451. <https://doi.org/10.1038/nm1388>.
- Jackaman, C., Radley-Crabb, H.G., Soffe, Z., Shavlakadze, T., Grounds, M.D., Nelson, D. J., 2013. Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice. *Aging Cell* 12, 345–357. <https://doi.org/10.1111/ace1.12062>.
- Jasilionis, M.G., 2018. Abnormal epigenetic regulation of immune system during aging. *Front. Immunol.* <https://doi.org/10.3389/fimmu.2018.00197>.
- Johnson, S.C., Rabinovitch, P.S., Kaerberlein, M., 2013. mTOR is a key modulator of ageing and age-related disease. *Nature*. <https://doi.org/10.1038/nature11861>.
- Ju, Z., Jiang, H., Jaworski, M., Rathinam, C., Gompf, A., Klein, C., Trumpp, A., Rudolph, K.L., 2007. Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment. *Nat. Med.* 13, 742–747. <https://doi.org/10.1038/nm1578>.
- Jung, H., Kim, D.O., Byun, J.E., Kim, W.S., Kim, M.J., Song, H.Y., Kim, Y.K., Kang, D.K., Park, Y.J., Kim, T.D., Yoon, S.R., Lee, H.G., Choi, E.J., Min, S.H., Choi, I., 2016. Thioredoxin-interacting protein regulates haematopoietic stem cell ageing and rejuvenation by inhibiting p38 kinase activity. *Nat. Commun.* 7 <https://doi.org/10.1038/ncomms13674>.
- Jylhävä, J., Pedersen, N.L., Hägg, S., 2017. Biological age predictors. *EBioMed.* <https://doi.org/10.1016/j.ebiom.2017.03.046>.
- Kaerberlein, M., 2020. RTB101 and immune function in the elderly: interpreting an unsuccessful clinical trial. *Transl. Med. Aging* 4, 32–34. <https://doi.org/10.1016/j.tma.2020.01.002>.
- Kamiya, T., Seow, S.V., Wong, D., Robinson, M., Campana, D., 2019. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. *J. Clin. Invest.* 129, 2094–2106. <https://doi.org/10.1172/JCI123955>.
- Kansal, R., Richardson, N., Neeli, I., Khawaja, S., Chamberlain, D., Ghani, M., Ghani, Qulain, Balazs, L., Beranova-Giorgianni, S., Giorgianni, F., Kochenderfer, J. N., Marion, T., Albritton, L.M., Radic, M., 2019. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. *Sci. Transl. Med.* 11, 1648. <https://doi.org/10.1126/scitranslmed.aav1648>.
- Keenan, C.R., Allan, R.S., 2019. Epigenomic drivers of immune dysfunction in aging. *Aging Cell.* <https://doi.org/10.1111/acer.12878>.
- Keren, Z., Naor, S., Nussbaum, S., Golan, K., Itkin, T., Sasaki, Y., Schmidt-Suppran, M., Lapidot, T., Melamed, D., 2011. B-cell depletion reactivates B lymphopoiesis in the BM and rejuvenates the B lineage in aging. *Blood* 117, 3104–3112. <https://doi.org/10.1182/blood-2010-09-307983>.
- Kim, M.-J., Miller, C.M., Shadrach, J.L., Wagers, A.J., Serwold, T., 2015. Young, proliferative thymic epithelial cells engraft and function in aging thymuses. *J. Immunol.* 194, 4784–4795. <https://doi.org/10.4049/jimmunol.1403158>.
- Kirkland, J.L., Tchkonja, T., 2017. Cellular senescence: a translational perspective. *EBioMed.* <https://doi.org/10.1016/j.ebiom.2017.04.013>.
- Kirkland, J.L., Tchkonja, T., 2020. Senolytic drugs: from discovery to translation. *J. Intern. Med.* 288, 518–536. <https://doi.org/10.1111/joim.13141>.
- Kityo, C., Makamdop, K.N., Rothenberger, M., Chipman, J.G., Hoskuldsson, T., Beilman, G.J., Grzywacz, B., Mugenyeni, P., Ssali, F., Akondy, R.S., Anderson, J., Schmidt, T.E., Reimann, T., Callisto, S.P., Schoephoerster, J., Schuster, J., Muloma, P., Ssengendo, P., Moysi, E., Petropoulos, A., Lanciotti, R., Zhang, L., Arévalo, M.T., Rodriguez, B., Ross, T.M., Trautmann, L., Sekaly, R.P., Lederman, M. M., Koup, R.A., Ahmed, R., Reilly, C., Douek, D.C., Schacker, T.W., 2018. Lymphoid tissue fibrosis is associated with impaired vaccine responses. *J. Clin. Invest.* 128, 2763–2773. <https://doi.org/10.1172/JCI97377>.
- Kogut, I., Scholz, J.L., Cancro, M.P., Cambier, J.C., 2012. B cell maintenance and function in aging. *Semin. Immunol.* <https://doi.org/10.1016/j.simm.2012.04.004>.
- Kovina, M.V., Karnaukhov, A.V., Krashenninikov, M.E., Kovin, A.L., Gazheev, S.T., Sergievich, L.A., Karnaukhova, E.V., Bogdanenko, E.V., Balyasin, M.V., Khodorigova, Y.M., Dyuzheva, T.G., Lyundup, A.V., 2019. Extension of maximal lifespan and high bone marrow chimerism after nonmyeloablative syngeneic transplantation of bone marrow from young to old mice. *Front. Genet.* 10, 310. <https://doi.org/10.3389/fgene.2019.00310>.
- Lanna, A., Gomes, D.C.O., Muller-Durovic, B., McDonnell, T., Escors, D., Gilroy, D.W., Lee, J.H., Karin, M., Akbar, A.N., 2017. A sestrin-dependent Erk-Jnk-p38 MAPK activation complex inhibits immunity during aging. *Nat. Immunol.* 18, 354–363. <https://doi.org/10.1038/ni.3665>.
- Lee, J., Yoon, S.R., Choi, I., Jung, H., 2019. Causes and mechanisms of hematopoietic stem cell aging. *Int. J. Mol. Sci.* <https://doi.org/10.3390/ijms20061272>.
- Leins, H., Mulaw, M., Eiwien, K., Sakk, V., Liang, Y., Denking, M., Geiger, H., Schirmbeck, R., 2018. Aged murine hematopoietic stem cells drive aging-associated immune remodeling. *Blood* 132, 565–576. <https://doi.org/10.1182/blood-2018-02-831065>.
- Lenti, E., Bianchessi, S., Proulx, S.T., Palano, M.T., Genovese, L., Raccosta, L., Spinelli, A., Drago, D., Andolfo, A., Alfano, M., Petrova, T.V., Mukenge, S., Russo, V., Brendolan, A., 2019. Therapeutic regeneration of lymphatic and immune cell functions upon lympho-organoid transplantation. *Stem Cell Rep.* 12, 1260–1268. <https://doi.org/10.1016/j.stemcr.2019.04.021>.
- Lévy, Y., Sereti, I., Tambussi, G., Routy, J.P., Lelièvre, J.D., Delfraissy, J.F., Molina, J.M., Fischl, M., Goujard, C., Rodriguez, B., Rouzioux, C., Avettand-Fenoël, V., Croughs, T., Beq, S., Morre, M., Poulin, J.F., Sekaly, R.P., Thiebaut, R., Lederman, M. M., 2012. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study - *PubMed. Clin. Infect. Dis.* 55, 291–300.
- Li, Z., Li, J., Bu, X., Liu, X., Tankersley, C.G., Wang, C., Huang, K., 2011. Age-induced augmentation of p38 MAPK phosphorylation in mouse lung. *Exp. Gerontol.* 46, 694–702. <https://doi.org/10.1016/j.exger.2011.04.005>.
- Liu, W., Du, W., Shang, X., Wang, L., Evelyn, C., Florian, M.C., A. Ryan, M., Rayes, A., Zhao, X., Setchell, K., Meller, J., Guo, F., Nassar, N., Geiger, H., Pang, Q., Zheng, Y., 2019. Rational identification of a Cdc42 inhibitor presents a new regimen for long-term hematopoietic stem cell mobilization. *Leukemia* 33, 749–761. <https://doi.org/10.1038/s41375-018-0251-5>.
- López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M., Kroemer, G., 2013. The hallmarks of aging. *Cell.* <https://doi.org/10.1016/j.cell.2013.05.039>.
- Madeo, F., Carmona-Gutierrez, D., Hofer, S.J., Kroemer, G., 2019. Caloric restriction mimetics against age-associated disease: targets, mechanisms, and therapeutic potential. *Cell Metab.* <https://doi.org/10.1016/j.cmet.2019.01.018>.
- Malaguarnera, L., 2019. Influence of resveratrol on the immune response. *Nutrients.* <https://doi.org/10.3390/nu11050946>.
- Mannick, J.B., Del Giudice, G., Lattanzi, M., Valiante, N.M., Praetgaard, J., Huang, B., Lonetto, M.A., Maecker, H.T., Kovarik, J., Carson, S., Glass, D.J., Klickstein, L.B., 2014. mTOR inhibition improves immune function in the elderly. *Sci. Transl. Med.* 6, 268ra179. <https://doi.org/10.1126/scitranslmed.3009892>.
- Mannick, J.B., Morris, M., Hockey, H.U., Roma, G., Beibel, M., Kulmatycki, K., Watkins, M., Shavlakadze, T., Zhou, W., Quinn, D., Glass, D.J., Klickstein, L.B., 2018. TORC1 inhibition enhances immune function and reduces infections in the elderly. *Sci. Transl. Med.* 10, 1564. <https://doi.org/10.1126/scitranslmed.aag1564>.
- Mannick, J.B., Teo, G., Bernardo, P., Quinn, D., Russell, K., Klickstein, L., Marshall, W., Shergill, S., 2021. Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials. *Lancet. Heal. Longev.* 2, e250–e262. [https://doi.org/10.1016/S2666-7568\(21\)00062-00063](https://doi.org/10.1016/S2666-7568(21)00062-00063).
- Martínez, P., Blasco, M.A., 2017. Telomere-driven diseases and telomere-targeting therapies. *J. Cell Biol.* <https://doi.org/10.1083/jcb.201610111>.
- Martínez-Zamudio, R.I., Dewald, H.K., Vasiliopoulos, T., Gittens-Williams, L., Fitzgerald-Bocarsly, P., Herbig, U., 2021. Senescence-associated  $\beta$ -galactosidase reveals the

- abundance of senescent CD8<sup>+</sup> T cells in aging humans. *Aging Cell* 20, e13344. <https://doi.org/10.1111/accel.13344>.
- Martin-Montalvo, A., Mercken, E.M., Mitchell, S.J., Palacios, H.H., Mote, P.L., Scheibye-Knudsen, M., Gomes, A.P., Ward, T.M., Minor, R.K., Blouin, M.J., Schwab, M., Pollak, M., Zhang, Y., Yu, Y., Becker, K.G., Bohr, V.A., Ingram, D.K., Sinclair, D.A., Wolf, N.S., Spindler, S.R., Bernier, M., De Cabo, R., 2013. Metformin improves healthspan and lifespan in mice. *Nat. Commun.* 4, 1–9. <https://doi.org/10.1038/ncomms3192>.
- Mathew, D., Giles, J.R., Baxter, A.E., Oldridge, D.A., Greenplate, A.R., Wu, J.E., Alani, C., Kuri-Cervantes, L., Pampena, M.B., D'Andrea, K., Manne, S., Chen, Z., Huang, Y.J., Reilly, J.P., Weisman, A.R., Ittner, C.A.G., Kuthuru, O., Dougherty, J., Nzingha, K., Han, N., Kim, J., Pattekar, A., Goodwin, E.C., Anderson, E.M., Weirick, M.E., Gouma, S., Arevalo, C.P., Bolton, M.J., Chen, F., Lacey, S.F., Ramage, H., Cherry, S., Hensley, S.E., Apostolidis, S.A., Huang, A.C., Vella, L.A., Betts, M.R., Meyer, N.J., Wherry, E.J., Alam, Z., Addison, M.M., Byrne, K.T., Chandra, A., Descamps, H.C., Kaminskiy, Y., Hamilton, J.T., Noll, J.H., Omran, D.K., Perkey, E., Prager, E.M., Poeschl, D., Shah, J.B., Shilan, J.S., Vanderbeck, A.N., 2020. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. *Science* (80-) 369. <https://doi.org/10.1126/SCIENCE.ABC8511>.
- Mattison, J.A., Wang, M., Bernier, M., Zhang, J., Park, S.S., Maudsley, S., An, S.S., Santhanam, L., Martin, B., Faulkner, S., Morrell, C., Baur, J.A., Peshkin, L., Sosnowska, D., Csiszar, A., Herbert, R.L., Tilmon, E.M., Ungvari, Z., Pearson, K.J., Lakatta, E.G., De Cabo, R., 2014. Resveratrol prevents high fat/sucrose diet-induced central arterial wall inflammation and stiffening in nonhuman primates. *Cell Metab.* 20, 183–190. <https://doi.org/10.1016/j.cmet.2014.04.018>.
- Meydani, S.N., Das, S.K., Pieper, C.F., Lewis, M.R., Klein, S., Dixit, V.D., Gupta, A.K., Villareal, D.T., Bhapkar, M., Huang, M., Fuss, P.J., Roberts, S.B., Holloszy, J.O., Fontana, L., 2016. Long-term moderate calorie restriction inhibits inflammation without impairing cell-mediated immunity: a randomized controlled trial in non-obese humans. *Aging (Albany, NY)* 8, 1416–1431. <https://doi.org/10.18632/aging.100994>.
- Michaud, J.P., Hallé, M., Lampron, A., Thériault, P., Préfontaine, P., Filali, M., Tributou-Jover, P., Lantaigne, A.M., Jodoin, R., Cluff, C., Brichard, V., Palmantier, R., Pilonnet, A., Larocque, D., Rivest, S., 2013. Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. *Proc. Natl. Acad. Sci. U. S. A.* 110, 1941–1946. <https://doi.org/10.1073/pnas.1215165110>.
- Min, D., Panoskaltis-Mortari, A., Kuro-o, M., Holländer, G.A., Blazar, B.R., Weinberg, K. I., 2007. Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. *Blood* 109, 2529–2537. <https://doi.org/10.1182/blood-2006-08-043794>.
- Mínhas, P.S., Latif-Hernandez, A., McReynolds, M.R., Durairaj, A.S., Wang, Q., Rubin, A., Joshi, A.U., He, J.Q., Gauba, E., Liu, L., Wang, C., Linde, M., Sugiura, Y., Moon, P.K., Majeti, R., Suematsu, M., Mochly-Rosen, D., Weissman, I.L., Longo, F.M., Rabinowitz, J.D., Andreasson, K.I., 2021. Restoring metabolism of myeloid cells reverses cognitive decline in ageing. *Nature*. <https://doi.org/10.1038/s41586-020-03160-0>.
- Naradikian, M.S., Myles, A., Beiting, D.P., Roberts, K.J., Dawson, L., Herati, R.S., Bengsch, B., Linderman, S.L., Stelekati, E., Spolski, R., Wherry, E.J., Hunter, C., Hensley, S.E., Leonard, W.J., Cancro, M.P., 2016. Cutting edge: IL-4, IL-21, and IFN- $\gamma$  interact to govern T-bet and CD11c expression in TLR-Activated B cells. *J. Immunol.* 197, 1023–1028. <https://doi.org/10.4049/jimmunol.1600522>.
- Nguyen, V., Mendelsohn, A., Larrick, J.W., 2017. Interleukin-7 and immunosenescence. *J. Immunol. Res.* <https://doi.org/10.1155/2017/4807853>.
- Nikzad, R., Angelo, L.S., Aviles-Padilla, K., Le, D.T., Singh, V.K., Bimler, L., Vukmanovic-Stejic, M., Vendrame, E., Ranganath, T., Simpson, L., Haigwood, N.L., Blish, C.A., Akbar, A.N., Paust, S., 2019. Human natural killer cells mediate adaptive immunity to viral antigens. *Sci. Immunol.* 4, 8116. <https://doi.org/10.1126/sciimmunol.aat8116>.
- Norden, D.M., Godbout, J.P., 2013. Review: microglia of the aged brain: primed to be activated and resistant to regulation. *Neuropathol. Appl. Neurobiol.* <https://doi.org/10.1111/j.1365-2990.2012.01306.x>.
- Novak, N., Koch, S., Allam, J.P., Bieber, T., 2010. Dendritic cells: bridging innate and adaptive immunity in atopic dermatitis. *J. Allergy Clin. Immunol.* 125, 50–59. <https://doi.org/10.1016/j.jaci.2009.11.019>.
- Oh, J., Wang, W., Thomas, R., Su, D.-M., 2020. Thymic rejuvenation via FOXN1-reprogrammed embryonic fibroblast (FEF) to counteract age-related inflammation. *JCI Insight*. <https://doi.org/10.1172/jci.insight.140313>.
- Pace, L., Goudot, C., Zueva, E., Gueguen, P., Burgdorf, N., Waterfall, J.J., Quivy, J.P., Almouzni, G., Amigorena, S., 2018. The epigenetic control of stemness in CD8<sup>+</sup> T cell fate commitment. *Science* (80-) 359, 177–186. <https://doi.org/10.1126/science.aah6499>.
- Palmer, S., Albergante, L., Blackburn, C.C., Newman, T.J., 2018. Thymic involution and rising disease incidence with age. *Proc. Natl. Acad. Sci. U. S. A.* 115, 1883–1888. <https://doi.org/10.1073/pnas.1714478115>.
- Pang, W.W., Price, E.A., Sahoo, D., Beeram, I., Maloney, W.J., Rossi, D.J., Schrier, S.L., Weissman, I.L., 2011. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. *Proc. Natl. Acad. Sci. U. S. A.* 108, 20012–20017. <https://doi.org/10.1073/pnas.1116110108>.
- Pangrazzi, L., Weinberger, B., 2020. T cells, aging and senescence. *Exp. Gerontol.* <https://doi.org/10.1016/j.exger.2020.110887>.
- Pangrazzi, L., Reidla, J., Carmona Arana, J.A., Naismith, E., Miggitsch, C., Meryk, A., Keller, M., Krause, A.A.N., Melzer, F.L., Trieb, K., Schirmer, M., Grubeck-Loebenstein, B., Weinberger, B., 2020. CD28 and CD57 define four populations with distinct phenotypic properties within human CD8<sup>+</sup> T cells. *Eur. J. Immunol.* 50, 363–379. <https://doi.org/10.1002/eji.201948362>.
- Park, S., Nahm, M.H., 2011. Older adults have a low capacity to opsonize pneumococci due to low igm antibody response to pneumococcal vaccinations. *Infect. Immun.* 79, 314–320. <https://doi.org/10.1128/IAI.00768-10>.
- Partridge, L., Fuentealba, M., Kennedy, B.K., 2020. The quest to slow ageing through drug discovery. *Nat. Rev. Drug Discov.* <https://doi.org/10.1038/s41573-020-0067-7>.
- Paust, S., Von Andrian, U.H., 2011. Natural killer cell memory. *Nat. Immunol.* <https://doi.org/10.1038/ni.2032>.
- Pereira, B.I., Akbar, A.N., 2016. Convergence of innate and adaptive immunity during human aging. *Front. Immunol.* <https://doi.org/10.3389/fimmu.2016.00445>.
- Pereira, B.I., Devine, O.P., Vukmanovic-Stejic, M., Chambers, E.S., Subramanian, P., Patel, N., Virasami, A., Sebire, N.J., Kinsler, V., Valdovinos, A., LeSaux, C.J., Passos, J.F., Antoniou, A., Rustin, M.H.A., Campisi, J., Akbar, A.N., 2019. Senescent cells evade immune clearance via HLA-E-mediated NK and CD8<sup>+</sup> T cell inhibition. *Nat. Commun.* 10. <https://doi.org/10.1038/s41467-019-10335-5>.
- Pereira, B.I., De Maeyer, R.P.H., Covre, L.P., Nehar-Belaid, D., Lanna, A., Ward, S., Marches, R., Chambers, E.S., Gomes, D.C.O., Riddell, N.E., Maini, M.K., Teixeira, V. H., Janes, S.M., Gilroy, D.W., Larbi, A., Mabbott, N.A., Ucar, D., Kuchel, G.A., Henson, S.M., Strid, J., Lee, J.H., Bancheureau, J., Akbar, A.N., 2020. Sestrins induce natural killer function in senescent-like CD8<sup>+</sup> T cells. *Nat. Immunol.* 21, 684–694. <https://doi.org/10.1038/s41590-020-0643-3>.
- Pluvinage, J.V., Haney, M.S., Smith, B.A.H., Sun, J., Iram, T., Bonanno, L., Li, L., Lee, D. P., Morgens, D.W., Yang, A.C., Shuken, S.R., Gate, D., Scott, M., Khatri, P., Luo, J., Bertozzi, C.R., Bassik, M.C., Wyss-Coray, T., 2019. CD22 blockade restores homeostatic microglial phagocytosis in ageing brains. *Nature* 568, 187–192. <https://doi.org/10.1038/s41586-019-1088-4>.
- Prattichizzo, F., Giuliani, A., Mensà, E., Sabbatinelli, J., De Nigris, V., Rippo, M.R., La Sala, L., Procopio, A.D., Olivieri, F., Ceriello, A., 2018. Pleiotropic effects of metformin: shaping the microbiome to manage type 2 diabetes and postpone ageing. *Ageing Res. Rev.* <https://doi.org/10.1016/j.arr.2018.10.003>.
- Quinn, K.M., Fox, A., Harland, K.L., Russ, B.E., Li, J., Nguyen, T.H.O., Loh, L., Olshanksy, M., Naeem, H., Tsyganov, D.C., Wiede, F., Webster, R., Blyth, C., Sng, X.Y. X., Tiganis, T., Powell, D., Doherty, P.C., Turner, S.J., Kedzierska, K., La Gruta, N.L., 2018. Age-related decline in primary CD8<sup>+</sup> t cell responses is associated with the development of senescence in virtual memory CD8<sup>+</sup> t cells. *Cell Rep.* 23, 3512–3524. <https://doi.org/10.1016/j.celrep.2018.05.057>.
- Rajagopalan, S., Long, E.O., 2012. Cellular senescence induced by CD158d reprograms natural killer cells to promote vascular remodeling. *Proc. Natl. Acad. Sci. U. S. A.* 109, 20596–20601. <https://doi.org/10.1073/pnas.1208248109>.
- Rajman, L., Chwalek, K., Sinclair, D.A., 2018. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. *Cell Metab.* <https://doi.org/10.1016/j.cmet.2018.02.011>.
- Ratliff, M., Alter, S., Frasca, D., Blomberg, B.B., Riley, R.L., 2013. In senescence, age-associated b cells secrete tnf $\alpha$  and inhibit survival of b-cell precursors. *Aging Cell* 12, 303–311. <https://doi.org/10.1111/accel.12055>.
- Rawji, K.S., Mishra, M.K., Michaels, N.J., Rivest, S., Stys, P.K., Wee Yong, V., 2016. Immunosenescence of Microglia and Macrophages: Impact on the Ageing Central Nervous System. <https://doi.org/10.1093/brain/awv395>.
- Rena, G., Hardie, D.G., Pearson, E.R., 2017. The mechanisms of action of metformin. *Diabetologia*. <https://doi.org/10.1007/s00125-017-4342-z>.
- Renshaw, M., Rockwell, J., Engleman, C., Gewirtz, A., Katz, J., Sambhara, S., 2002. Cutting edge: impaired toll-like receptor expression and function in aging. *J. Immunol.* 169, 4697–4701. <https://doi.org/10.4049/jimmunol.169.9.4697>.
- Rink, L., Cakman, I., Kirchner, H., 1998. Altered cytokine production in the elderly. *Mechanisms of Ageing and Development*. Elsevier, pp. 199–209. [https://doi.org/10.1016/S0047-6374\(97\)00153-X](https://doi.org/10.1016/S0047-6374(97)00153-X).
- Rode, I., Martins, V.C., Küblbeck, G., Maltry, N., Tessmer, C., Rodewald, H.-R., 2015. Foxn1 protein expression in the developing, aging, and regenerating Thymus. *J. Immunol.* 195, 5678–5687. <https://doi.org/10.4049/jimmunol.1502010>.
- Rodriguez-Zhurbenko, N., Quach, T.D., Hopkins, T.J., Rothstein, T.L., Hernandez, A.M., 2019. Human B-1 cells and B-1 cell antibodies change with advancing age. *Front. Immunol.* 10, 483. <https://doi.org/10.3389/fimmu.2019.00483>.
- Rosenberg, S.A., Sportès, C., Ahmadzadeh, M., Fry, T.J., Ngo, L.T., Schwarz, S.L., Stetler-Stevenson, M., Morton, K.E., Mavroukakis, S.A., Morre, M., Buffet, R., Mackall, C.L., Gress, R.E., 2006. IL-7 administration to humans leads to expansion of CD8<sup>+</sup> and CD4<sup>+</sup> cells but a relative decrease of CD4<sup>+</sup> T-Regulatory cells. *J. Immunother.* 29, 313–319. <https://doi.org/10.1097/01.cji.0000210386.55951.c2>.
- Rossi, D.J., Bryder, D., Zahn, J.M., Ahlenius, H., Sonu, R., Wagers, A.J., Weissman, I.L., 2005. Cell intrinsic alterations underlie hematopoietic stem cell aging. *Proc. Natl. Acad. Sci. U. S. A.* 102, 9194–9199. <https://doi.org/10.1073/pnas.0503280102>.
- Rübe, C.E., Fricke, A., Widmann, T.A., Fürst, T., Madry, H., Pfreundschuh, M., Rübe, C., 2011. Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging. *PLoS One* 6. <https://doi.org/10.1371/journal.pone.0017487>.
- Rubtsov, A.V., Marrack, P., Rubtsova, K., 2017. T-bet expressing B cells – novel target for autoimmune therapies? *Cell. Immunol.* 321, 35–39. <https://doi.org/10.1016/j.cellimm.2017.04.011>.
- Rydzynski Moderbacher, C., Ramirez, S.I., Dan, J.M., Grifoni, A., Hastie, K.M., Weiskopf, D., Belanger, S., Abbott, R.K., Kim, C., Choi, J., Kato, Y., Crotty, E.G., Kim, C., Rawlings, S.A., Mateus, J., Tse, L.P.V., Frazier, A., Baric, R., Peters, B., Greenbaum, J., Ollmann Saphire, E., Smith, D.M., Sette, A., Crotty, S., 2020. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. *Cell* 0. <https://doi.org/10.1016/j.cell.2020.09.038>.

- Sallusto, F., Lanzavecchia, A., 2002. The instructive role of dendritic cells on T-cell responses. *Arthritis Res.* <https://doi.org/10.1186/ar567>.
- Sayed, N., Gao, T., Tibshirani, R., Hastie, T., Cui, L., Kuznetsova, T., Rosenberg-Hasson, Y., Ostan, R., Monti, D., Lehallier, B., Shen-Orr, S., Maecker, H.T., Dekker, C. L., Wyss-Coray, T., Franceschi, C., Jovic, V., Haddad, F., Montoya, J.G., Wu, J.C., Furman, D., 2019. An inflammatory clock predicts multi-morbidity, immunosenescence and cardiovascular aging in humans. *bioRxiv* 840363. <https://doi.org/10.1101/840363>.
- Scharer, C.D., Bally, A.P.R., Gandham, B., Boss, J.M., 2017. Cutting edge: chromatin accessibility programs CD8 T cell memory. *J. Immunol.* 198, 2238–2243. <https://doi.org/10.4049/jimmunol.1602086>.
- Shirakawa, K., Yan, X., Shinmura, K., Endo, J., Kataoka, M., Katsumata, Y., Yamamoto, T., Anzai, A., Isobe, S., Yoshida, N., Itoh, H., Manabe, I., Sekai, M., Hamazaki, Y., Fukuda, K., Minato, N., Sano, M., 2016. Obesity accelerates T cell senescence in murine visceral adipose tissue. *J. Clin. Invest.* 126, 4626–4639. <https://doi.org/10.1172/JCI88606>.
- Simon, M., Van Meter, M., Ablava, J., Ke, Z., Gonzalez, R.S., Taguchi, T., De Cecco, M., Leonova, K.I., Kogan, V., Helfand, S.L., Neretti, N., Roichman, A., Cohen, H.Y., Meer, M.V., Gladyshev, V.N., Antoch, M.P., Gudkov, A.V., Sedivy, J.M., Seluanov, A., Gorbunova, V., 2019. LINE1 derepression in aged wild-type and SIRT6-deficient mice drives inflammation. *Cell Metab.* 29, 871–885. <https://doi.org/10.1016/j.cmet.2019.02.014> e5.
- Singh, A.K., McGuirk, J.P., 2020. CAR T cells: continuation in a revolution of immunotherapy. *Lancet Oncol.* [https://doi.org/10.1016/S1470-2045\(19\)30823-X](https://doi.org/10.1016/S1470-2045(19)30823-X).
- Soraas, A., Matsuyama, M., de Lima, M., Wald, D., Buechner, J., Gedde-Dahl, T., Soraas, C.L., Chen, B., Ferrucci, L., Dahl, J.A., Horvath, S., Matsuyama, S., 2019. Epigenetic age is a cell-intrinsic property in transplanted human hematopoietic cells. *Aging Cell* 18. <https://doi.org/10.1111/acel.12897>.
- Song, P., An, J., Zou, M.-H., 2020. Immune clearance of senescent cells to combat ageing and chronic diseases. *Cells* 9, 671. <https://doi.org/10.3390/cells9030671>.
- Soukas, A.A., Hao, H., Wu, L., 2019. Metformin as anti-aging therapy: is it for everyone? *Trends Endocrinol. Metab.* <https://doi.org/10.1016/j.tem.2019.07.015>.
- Sportès, C., Babb, R.R., Krumlauf, M.C., Hakim, F.T., Steinberg, S.M., Chow, C.K., Brown, M.R., Fleisher, T.A., Noel, P., Maric, I., Stetler-Stevenson, M., Engel, J., Buffet, R., Morre, M., Amato, R.J., Pecora, A., Mackall, C.L., Gress, R.E., 2010. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. *Clin. Cancer Res.* 16, 727–735. <https://doi.org/10.1158/1078-0432.CCR-09-1303>.
- Sprent, J., Surh, C.D., 2011. Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells. *Nat. Immunol.* <https://doi.org/10.1038/ni.2018>.
- Stahl, E.C., Brown, B.N., 2015. Cell therapy strategies to combat immunosenescence. *Organogenesis* 11, 159–172. <https://doi.org/10.1080/15476278.2015.1120046>.
- Stebegg, M., Bignon, A., Hill, D.L., Silva-Cayetano, A., Krueger, C., Vanderleyden, I., Innocenti, S., Boon, L., Wang, J., Zand, M.S., Dooley, J., Clark, J., Liston, A., Carr, E., Linterman, M.A., 2020. Rejuvenating conventional dendritic cells and T follicular helper cell formation after vaccination. *Life* 9. <https://doi.org/10.7554/eLife.52473>.
- Strong, R., Miller, R.A., Antebi, A., Astle, C.M., Bogue, M., Denzel, M.S., Fernandez, E., Flurkey, K., Hamilton, K.L., Lamming, D.W., Javors, M.A., de Magalhães, J.P., Martinez, P.A., McCord, J.M., Miller, B.F., Müller, M., Nelson, J.F., Ndikum, J., Rainger, G.E., Richardson, A., Sabatini, D.M., Salmon, A.B., Simpkins, J.W., Steegenga, W.T., Nadon, N.L., Harrison, D.E., 2016. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an  $\alpha$ -glucosidase inhibitor or a Nrf2-inducer. *Aging Cell* 15, 872–884. <https://doi.org/10.1111/acel.12496>.
- Sun, L., Guo, J., Brown, R., Amagai, T., Zhao, Y., Su, D.M., 2010. Declining expression of a single epithelial cell-autonomous gene accelerates age-related thymic involution. *Aging Cell* 9, 347–357. <https://doi.org/10.1111/j.1474-9726.2010.00559.x>.
- Sun, D., Luo, M., Jeong, M., Rodriguez, B., Xia, Z., Hannah, R., Wang, H., Le, T., Faull, K. F., Chen, R., Gu, H., Bock, C., Meissner, A., Göttgens, B., Darlington, G.J., Li, W., Goodell, M.A., 2014. Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal. *Cell Stem Cell* 14, 673–688. <https://doi.org/10.1016/j.stem.2014.03.002>.
- Taiwo, O., Wilson, G.A., Emmett, W., Morris, T., Bonnet, D., Schuster, E., Adejumo, T., Beck, S., Pearce, D.J., 2013. DNA methylation analysis of murine hematopoietic side population cells during aging. *Epigenetics* 8, 1114–1122. <https://doi.org/10.4161/epi.26017>.
- Tedone, E., Huang, E., O'Hara, R., Batten, K., Ludlow, A.T., Lai, T.-P., Arosio, B., Mari, D., Wright, W.E., Shay, J.W., 2019. Telomere length and telomerase activity in T cells are biomarkers of high-performing centenarians. *Aging Cell* 18, e12859. <https://doi.org/10.1111/acel.12859>.
- Thomas, R., Wang, W., Su, D.M., 2020. Contributions of age-related thymic involution to immunosenescence and inflammaging. *Immun. Ageing.* <https://doi.org/10.1186/s12979-020-0173-8>.
- Thompson, H.L., Smithey, M.J., Uhrhlab, J.L., Jęfici, I., Jęrgović, M., White, S.E., Carrier, N., Lang, A.M., Okoye, A., Park, B., Picker, L.J., Surh, C.D., Nikolich-Zugich, J., 2019. Lymph nodes as barriers to T-cell rejuvenation in aging mice and nonhuman primates. *Aging Cell* 18. <https://doi.org/10.1111/acel.12865>.
- Tortorella, C., Piazolla, G., Spaccavento, F., Pece, S., Jirillo, E., Antonaci, S., 1998. Spontaneous and fas-induced apoptotic cell death in aged neutrophils. *J. Clin. Immunol.* 18, 321–329. <https://doi.org/10.1023/A:1023286831246>.
- Trédan, O., Ménétrier-Caux, C., Ray-Coquard, I., Garin, G., Crozet, C., Verronèse, E., Bachelot, T., Rebattu, P., Heudel, P.E., Cassier, P., Chabaud, S., Croughs, T., Dupont, P., Cadore, A.C., Clapissou, G., Delgado, A., Bardin-dit-Courageot, C., Rigal, C., N'Kodia, A., Gilles-Alfchain, L., Morre, M., Pérol, D., Blay, J.Y., Caux, C., 2015. ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. *Ann. Oncol.* 26, 1353–1362. <https://doi.org/10.1093/annonc/mdv173>.
- Ucar, D., Márquez, E.J., Chung, C.H., Marches, R., Rossi, R.J., Uyar, A., Wu, T.C., George, J., Stitzel, M.L., Karolina Palucka, A., Kuchel, G.A., Banchereau, J., 2017. The chromatin accessibility signature of human immune aging stems from CD8+ T cells. *J. Exp. Med.* 214, 3123–3144. <https://doi.org/10.1084/jem.20170416>.
- Umbayev, B., Masoud, A.R., Tsou, A., Alimbetov, D., Olzhayev, F., Shramko, A., Kairylykyzy, A., Safarova, Y., Davis, T., Askarova, S., 2018. Elevated levels of the small GTPase Cdc42 induces senescence in male rat mesenchymal stem cells. *Biogerontology* 19, 287–301. <https://doi.org/10.1007/s10522-018-9757-5>.
- United Nations, 2019. *World Population Prospects 2019 Highlights*.
- Vaidya, H.J., Briones Leon, A., Blackburn, C.C., 2016. FOXN1 in thymus organogenesis and development. *Eur. J. Immunol.* <https://doi.org/10.1002/eji.201545814>.
- van Beek, A.A., Van den Bossche, J., Mastroberardino, P.G., de Winther, M.P.J., Leenen, P.J.M., 2019. Metabolic Alterations in Aging Macrophages: Ingredients for Inflammaging? *Trends Immunol.* <https://doi.org/10.1016/j.it.2018.12.007>.
- Van Beek, A.A., Fransen, F., Meijer, B., De Vos, P., Knol, E.F., Savelkoul, H.F.J., 2018. Aged mice display altered numbers and phenotype of basophils, and bone marrow-derived basophil activation, with a limited role for aging-associated microbiota. *Immun. Ageing* 15. <https://doi.org/10.1186/s12979-018-0135-6>.
- van Splunter, M., Perdijk, O., Fick-Brinkhof, H., Floris-Vollenbroek, E.G., Meijer, B., Brugman, S., Savelkoul, H.F.J., van Hoffen, E., Joost van Neerven, R.J., 2019. Plasmacytoid dendritic cell and myeloid dendritic cell function in ageing: a comparison between elderly and young adult women. *PLoS One* 14, e0225825. <https://doi.org/10.1371/journal.pone.0225825>.
- Vasamsetti, S.B., Karnewar, S., Kanugula, A.K., Thatipalli, A.R., Kumar, J.M., Kotamraju, S., 2015. Metformin inhibits monocyte- To-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. *Diabetes* 64, 2028–2041. <https://doi.org/10.2337/db14-1225>.
- Verity, R., Okell, L.C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P.G.T., Fu, H., Dighe, A., Griffin, J.T., Baguelin, M., Bhatia, S., Boonyasiri, A., Cori, A., Cucunubá, Z., FitzJohn, R., Gaythorpe, K., Green, W., Hamlet, A., Hinsley, W., Laydon, D., Nedjati-Gilani, G., Riley, S., van Elsland, S., Volz, E., Wang, H., Wang, Y., Xi, X., Donnelly, C.A., Ghani, A.C., Ferguson, N.M., 2020. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect. Dis.* 20, 669–677. [https://doi.org/10.1016/S1473-3099\(20\)30243-30247](https://doi.org/10.1016/S1473-3099(20)30243-30247).
- Verovskaya, E., Broekhuis, M.J.C., Zwart, E., Ritsema, M., van Os, R., de Haan, G., Bystryk, L.V., 2013. Heterogeneity of young and aged murine hematopoietic stem cells revealed by quantitative clonal analysis using cellular barcoding. *Blood* 122, 523–532. <https://doi.org/10.1182/blood-2013-01-481135>.
- Walford, R.L., 1969. The immunologic theory of aging. *Immunol. Rev.* 2 <https://doi.org/10.1111/j.1600-065X.1969.tb00210.x>, 171–171.
- Wang, J., Lu, X., Sakk, V., Klein, C.A., Rudolph, K.L., 2014. Senescence and apoptosis block hematopoietic activation of quiescent hematopoietic stem cells with short telomeres. *Blood* 124, 3237–3240. <https://doi.org/10.1182/blood-2014-04-568055>.
- Wang, W., Jiang, J., Wu, C., 2020. CAR-NK for tumor immunotherapy: clinical transformation and future prospects. *Cancer Lett.* <https://doi.org/10.1016/j.canlet.2019.11.033>.
- Watad, A., Bragazzi, N.L., Adawi, M., Amital, H., Toubi, E., Porat, B.S., Shoenfeld, Y., 2017. Autoimmunity in the elderly: insights from basic science and clinics - a mini-review. *Gerontology.* <https://doi.org/10.1159/000478012>.
- Weng, Nping, Akbar, A.N., Goronzy, J., 2009. CD28- T cells: their role in the age-associated decline of immune function. *Trends Immunol.* <https://doi.org/10.1016/j.it.2009.03.013>.
- Wertheimer, T., Velardi, E., Tsai, J., Cooper, K., Xiao, S., Kloss, C.C., Ottmüller, K.J., Mokhtari, Z., Brede, C., deRoos, P., Kinsella, S., Palikuqi, B., Ginsberg, M., Young, L. F., Kreines, F., Lieberman, S.R., Lazrak, A., Guo, P., Malard, F., Smith, O.M., Shono, Y., Jenq, R.R., Hanash, A.M., Nolan, D.J., Butler, J.M., Beilhack, A., Manley, N.R., Rafii, S., Dudakov, J.A., van den Brink, M.R.M., 2018. Production of BMP4 by endothelial cells is crucial for endogenous thymic regeneration. *Sci. Immunol.* 3 <https://doi.org/10.1126/sciimmunol.aal2736>.
- Weyand, C.M., Goronzy, J.J., 2016. Aging of the immune system: mechanisms and therapeutic targets, in: *Annals of the American Thoracic Society*. *Am. Thoracic Soc.* S422–S428. <https://doi.org/10.1513/AnnalsATS.201602-095AW>.
- White, M.J., Beaver, C.M., Goodier, M.R., Bottomley, C., Nielsen, C.M., Wolf, A.S.F.M., Boldrin, L., Whitmore, C., Morgan, J., Pearce, D.J., Riley, E.M., 2017. Calorie restriction attenuates terminal differentiation of immune cells. *Front. Immunol.* 7, 667. <https://doi.org/10.3389/fimmu.2016.00667>.
- Whiting, C.C., Siebert, J., Newman, A.M., Du, H.W., Alizadeh, A.A., Goronzy, J., Weyand, C.M., Krishnan, E., Garrison Fathman, C., Maecker, H.T., 2015. Large-scale and comprehensive immune profiling and functional analysis of normal human aging. *PLoS One* 10. <https://doi.org/10.1371/journal.pone.0133627>.
- Xu, M., Pirtskhalava, T., Farr, J.N., Weigand, B.M., Palmer, A.K., Weivoda, M.M., Inman, C.L., Ogrodnik, M.B., Hachfeld, C.M., Fraser, D.G., Onken, J.L., Johnson, K. O., Verzosa, G.C., Langhi, L.G.P., Weigl, M., Giorgadze, N., LeBrasseur, N.K., Miller, J.D., Jurk, D., Singh, R.J., Allison, D.B., Ejima, K., Hubbard, G.B., Ikeno, Y., Cubro, H., Garovic, V.D., Hou, X., Weroha, S.J., Robbins, P.D., Niedermhofer, L.J., Khosla, S., Tchkonja, T., Kirkland, J.L., 2018. Senolytics improve physical function and increase lifespan in old age. *Nat. Med.* 24, 1246–1256. <https://doi.org/10.1038/s41591-018-0092-9>.
- Yager, E.J., Ahmed, M., Lanzer, K., Randall, T.D., Woodland, D.L., Blackman, M.A., 2008. Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. *J. Exp. Med.* 205, 711–723. <https://doi.org/10.1084/jem.20071140>.



- Yamanaka, M., Ishikawa, T., Griep, A., Axt, D., Kummer, M.P., Heneka, M.T., 2012. PPAR $\gamma$ /RXRA-induced and CD36-mediated microglial amyloid- $\beta$  phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. *J. Neurosci.* 32, 17321–17331. <https://doi.org/10.1523/JNEUROSCI.1569-12.2012>.
- Ye, J., Huang, X., Hsueh, E.C., Zhang, Q., Ma, C., Zhang, Y., Varvares, M.A., Hoft, D.F., Peng, G., 2012. Human regulatory T cells induce T-lymphocyte senescence. *Blood* 120, 2021–2031. <https://doi.org/10.1182/blood-2012-03-416040>.
- Yoshida, K., Cologne, J.B., Cordova, K., Misumi, M., Yamaoka, M., Kyoizumi, S., Hayashi, T., Robins, H., Kusunoki, Y., 2017. Aging-related changes in human T-cell repertoire over 20 years delineated by deep sequencing of peripheral T-cell receptors. *Exp. Gerontol.* 96, 29–37. <https://doi.org/10.1016/j.exger.2017.05.015>.
- Yoshida, S., Nakagami, H., Hayashi, H., Ikeda, Y., Sun, J., Tenma, A., Tomioka, H., Kawano, T., Shimamura, M., Morishita, R., Rakugi, H., 2020. The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. *Nat. Commun.* 11, 1–10. <https://doi.org/10.1038/s41467-020-16347-w>.
- Yousefzadeh, M.J., Flores, R.R., Zhu, Y., Schmiechen, Z.C., Brooks, R.W., Trussoni, C.E., Cui, Y., Angelini, L., Lee, K.-A., McGowan, S.J., Burrack, A.L., Wang, D., Dong, Q., Lu, A., Sano, T., O'Kelly, R.D., McGuckian, C.A., Kato, J.I., Bank, M.P., Wade, E.A., Pillai, S.P.S., Klug, J., Ladiges, W.C., Burd, C.E., Lewis, S.E., LaRusso, N.F., Vo, N.V., Wang, Y., Kelley, E.E., Huard, J., Stromnes, I.M., Robbins, P.D., Niedernhofer, L.J., 2021. An aged immune system drives senescence and ageing of solid organs. *Nature* 1–6. <https://doi.org/10.1038/s41586-021-03547-7>.
- Zhang, H., Alsaleh, G., Feltham, J., Sun, Y., Napolitano, G., Riffelmacher, T., Charles, P., Frau, L., Hublitz, P., Yu, Z., Mohammed, S., Ballabio, A., Balabanov, S., Mellor, J., Simon, A.K., 2019. Polyamines control eIF5A hypusination, TFEB translation, and autophagy to reverse B cell senescence. *Mol. Cell* 76, 110–125. <https://doi.org/10.1016/j.molcel.2019.08.005> e9.